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Pulmonary and Generalized Lysosomal
Storage Induced by Amphiphilic Drugs
by Zdenek Hruban*
Administration of amphiphilic drugs to experimental animals causes formation of myelinoid bodies in
many cell types, accumulation of foamy macrophages in pulmonary alveoli and pulmonary alveolar
proteinosis. These changes are the result of an interaction between the drugs and phospholipids which
leads to an alteration in physicochemical properties of the phospholipids. Impairment of the digestion of
altered pulmonary secretions in phagosomes of macrophages results in accumulation of foam cells in
pulmonary alveoli. Impairment ofthe metabolism ofaltered phospholipids removed by autophagy induces
an accumulation of myelinoid bodies. The administration of amphiphilic compounds thus causes
pulmonary intra-alveolar histiocytosis which is a part of a drug-induced lysosomal storage or generalized
lipidosis.
The accumulation ofdrug-lipid complexes in myelinoid bodies and in pulmonary foam cells may lead to
alteration of cellular functioning and to clinical disease. Currently over 50 amphiphilic drugs are known.
Unique pharmacological properties necessitate clinical use of some of these drugs. The occurrence and
severity of potential clinical side effects depend on the nature of each drug, dosage and duration of
treatment, simultaneous administration of other drugs and foods, individual metabolic pattern of the
patient and other factors. Further studies on factors preventing and potentiating adverse effects of
amphiphilic drugs are indicated.
In recent years it has become apparent that certain
drugs administered systematically to man have serious
side effects because of their affinity for the lungs. The
pulmonary pathology produced by these drugs has
received relatively little clinical attention because ofthe
insidious and chronic nature of its development. With
increasing awareness that a large variety of seemingly
harmless drugs can induce such lung changes, it is
imperative that more rigorous studies be carried out
before such drugs are put to clinical use. The purpose of
this report is to review a group of drugs which lead to
intra-alveolar histiocytosis and to generalized lysosomal
storage.
Foam Cells
In 1966, Greselinreported (1)thatchronic administra-
tion of a drug which inhibits cholesterol synthesis,
trans-1,4-bis(2-chlorobenzylaminomethyl)cyclohexane
dichloride, also called AY-9944, induces accumulation of
foamcells inpulmonary alveoli ofexperimental animals.
In the past 15 years other drugs with a variety of
pharmacological effects were shown to produce similar
pulmonary side effects (Table 1).
These drugs induce essentially similar histological
and ultrastructural changes in the lung, although the
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time required for the appearance of the foam cells and
their quantity and size may be quite different in various
animal species (1-4). The lungs of the treated animals
increase in weight (1,5) and contain whitish plaques and
nodules on gross examination (1,6). Microscopically
these plaques consist ofintra-alveolar accumulations of
foam cells (1,7).
The foam cells are between 20 and 80 ,um in diameter
(4,8-10) and have a centrally placed nucleus. The
cytoplasm is abundant, pale, and finely reticulated in
hematoxylin-eosin stained sections (Fig. 1). In toluidine
blue-stained Epon sections, the foam cells are filled
with numerous round inclusions. Staining of foam cells
with Sudan Black B and with Baker's acid hematein for
phospholipids are positive, while staining with Sudan
III and by the periodic acid-Schiff method are usually
negative (5,7,10,11). Examination of fresh tissues in
polarized light identifies both the inclusions in foam
cells and myelinoid bodies as Maltese cross figures
(11,12). Histochemical studies reveal high activities of
acid phosphatase and P-glucuronidase, implicating the
foam cells as macrophages (4,10,13,14).
The time sequence of pulmonary changes associated
with foam cell accumulation has been studied at light
and electron microscopic levels. The first change ob-
served in iprindole-treated rats is interstitial pulmo-
nary edema associated with degenerative changes in
capillary endothelia (14). Subsequently endothelia and
alveolar epithelia become swollen and the septa infil-Z. HRUBAN
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trated by interstitial macrophages (14). The lungs of
chlorphentermine-treated rats show hyperemia, aggre-
gation of leucocytes in venules and perivascular infil-
tration by monocytes during the first week oftreatment
(4). Ingeneral, afewintra-alveolar macrophages appear
early and become progressively larger, binucleated, and
more numerous (5,7,10,15). These macrophages are
derived from interstitial macrophages (10,16), which in
turn originate fromblood monocytes (4,17). In histologi-
cal sections the alveolar lumina contain abundant amor-
phous material. On ultrastructural examination the
material is identified as secretions derived from secre-
tory vacuoles ofgranular pneumocytes (Figs. 2 and 3).
It has been shown (7,18,19) that the intra-alveolar
macrophages phagocytize the secretions, which are rich
in dipalmitoyllecithin (9), and become foam cells (Fig.
4). After 3-6 weeks of treatment, the foam cells are
numerous (4,7,8,16).
FIGURE 1 Densely packed foam cells in alveolar lumina ofa rat fed
chlorcyclizine. Hematoxylin-eosin, x 590.
FIGURE 2. Portion of an alveolus filled with concentric and tubular
secretions from a rat treated with chlorcyclizine. x6900.
A marked decrease in the secretory activity ofType
II pneumocytes is observed after 9 months oftreatment
(20). After 12months ofiprindole feeding, the accumula-
tions of foam cells are replaced by pale eosinophilic
granular material in the intra-alveolar spaces as a
result of cellular breakdown, and the histological pic-
ture is that ofalveolar proteinosis (20). Chronic admini-
stration ofchlorphentermine and ofAY-9944 will lead to
similar changes (1,21). Ifthe administration ofthe drug
is withdrawn after several weeks oftreatment, the size,
the number of foam cells, the ultrastructure and en-
zyme activities willnormalize in2-5 weeks (7,10,22-24).
During this process the secretions in phagosomes of
macrophages are replaced by electron dense heteroge-
neous material (7). The current knowledge of the
alveolar macrophage in drug-induced lipidoses has been
reviewed by Reasor (23).
FIGURE 3. Secretion of a granular pneumocyte from a rat treated
with chlorcyclizine (302). x5600.
FIGURE 4. Foamyalveolarmacrophagewithphagocytized secretions
from a rat treated wtih chlorcyclizine. x4000.
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Myelinoid Bodies
Several pulmonary cells show striking changes follow-
ing treatment with amphiphilic drugs (AP drugs). Type
II pneumocytes become hypertrophic and hyperplastic
after triparanol and chlorcyclizine treatment (7,8) but
do not show changes after chlorphentermine treatment
(10). The secretory vacuoles of Type II pneumocytes
become enlarged (7,14). Myelinoid bodies (25,26) and
heterogeneous dense bodies appear in the cytoplasm of
Tlype I pneumocytes (Fig. 5), ciliatedbronchiolarepithe-
lia and Clara cells, smooth muscle cells, fibroblasts and
capillary endothelia (Table 1).
Drug-induced myelinoid bodies (DIM bodies) are
secondary lysosomes containing lamellar, reticular or
crystalloid material (Figs. 6 and 7). The lamellae form
concentric layers with a 40 to 45 A periodicity (27).
Reticular or crystalloid myelinoid bodies are found in
various pulmonary cells, but not in pulmonary macro-
phages (90). Heterogeneous dense bodies are secondary
lysosomes filled with heterogeneous material.
Myelinoid bodies have received a variety of names.
The original term myeloid body (25,26,28) should be, in
the opinion of Ghadially (29), replaced by the more
appropriate term myelinoid body. Other investigators
prefer to use terms such as body, inclusion or lysosome
preceded by adjectives such as lamellar, lamellate,
multilamellate, honeycomblike andmembranous. Names
which do not differentiate between membrane-bound
myelinoid bodies and myelin figures without limiting
membranes should be avoided.
The drugs which induce accumulations of pulmonary
FIGURE 5. ype I pneumocytes from a rat fed chlorcyclizine for 5 weeks. The upper cell contains numerous myelinoid bodies. The lower cell
contains heterogeneous dense bodies and material resembling alveolar secretions. x 15,600.DRUG-INDUCED PULMONARY HISTIOCYTOSIS
FIGURE 7. Crystalloid type of a myelinoid body from the corpus
luteum of a chlorcycizine-treated rat. x22,400.
FIGURE 6. Myelinoid bodies induced in a rat hepatocyte by chlor-
cyclizine. The upperbody is ofthe reticular type, the lower body is
of the mixed type. x23,400.
foam cells also induce the formation ofmyelinoid bodies
in many othercell types ofextrapulmonary tissues (Fig.
8) both in vivo (Table 2) and in vitro (Table 3). High
doses of chlorphentermine, chloramitryptiline, RM1
10.393, and erythromycin induce formation offoam cells
at extrapulmonary sites particularly in lymph nodes,
spleen and thymus (11,30). Patients treated with
diethylaminoethoxyhexestrol (DEAEH) have foamy
cells with deep blue granules in their bone marrow
(31,32), spleen and lymph nodes (33). Foam cells do not,
however, appear in similarly treated rats (34).
Because the inclusions in foam cells and the DIM-
bodies are modified lysosomes, knowledge of lysosome
formation by heterophagy and by autophagy is neces-
sary to understand their nature (26,35). In autophagy,
sequestering cisternae surround a portion of the cyto-
plasm containing organelles and form an autophagic
vacuole. The thin membranes of the sequestering
cisterna are then transformed into a thick limiting
membrane ofthe lysosome. Hydrolytic enzymes formed
in endoplasmic reticulum are brought to the autophagic
vacuole within primary lysosomes. The sequestered
organelles are broken down by the hydrolytic enzymes
and the autophagic vacuole changes into a heteroge-
neous dense body (secondary lysosome). Further diges-
tion leads to the appearance of smaller homogeneous
bodies (residual bodies). In heterophagy, the extracellu-
lar material enters the cell within pinocytotic vesicles
and phagocytic vacuoles. Primary lysosomes empty
their enzymes into this vacuole, and the digestion
proceeds as in autophagy.
If the degradation of substrates sequestered within
lysosomes is impaired, the substrates will accumulate,
and the lysosomes will become storage bodies. Lyso-
somal digestion maybe impaired by several mechanisms
(36,37). For example, each of the human storage dis-
eases is caused by the absence of a specific lysosomal
enzyme. Myelinoid bodies are storage bodies containing
lipids of membranes whose digestion is impaired by
drugs (18). The inclusions in foam cells are phagosomes
containing phagocytized pulmonary secretions whose
digestion is impaired by drugs.
The inclusions in foam cells (Fig. 4) and the DIM
bodies (Fig. 6) should be differentiated from secretory
granules ofTIype II pneumocytes (38) (Fig. 3). All three
structures are limited by a 90 A thick membrane and
contain lamellar material. The lamellae within phago-
somes of pulmonary macrophages are less densely
packed and less orderly arranged than those of DIM
bodies. Tangential cuts through myelinoid bodies can
obscure the outlines ofthe limiting membrane, leading
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Table 3. Inducers of myelinoid bodies in vitro systems.a
Culture Culture
Thera- Amphi- of Culture of
Drugs and chemicals: peutic philic nervous of other Other
name, generic (brand)b usec molecule tissue macrophages cells systems References
Acridine orange + (280)
1-Amino-4-octylpiperazine, AP22 F + + (281)
1,7-bis(p-Aminophenoxy)heptane, 153C51 w + d,e (282,108)
Amitriptyline H + + (283)
AY 9944 T + + (215)
Benzylidine-1-aminopiperazine, AP8 F + + (281)
Bilirubin 0 + (284,285)
Brompheniramine L + + (257)
Chloroquine M + + + + f (107,290-292)
Chlorpheniramine (Teldrin) L + + (257)
Chlorpromazine (Thorazine) V + + + g (188,283,293)
Clociguanil M + + (41)
Diethylaminoethoxyhexestrol E + + (286)
Gentamycin F 0 + (210)
6-Hydroxydopamine 0 + (211)
Lysergide HXY + + (172)
Mesoridazine (Serentil) OX + + (258)
Mianserine (Tolvin) LNY + + (257)
Myoinositol 0 + (287)
Nortriptyline H + + (258)
Perhexiline ET + + + (73,294,295)
Pheniramine L + + (257)
Phentermine C + + (283)
Promethazine (Phenergan) JL + + (288)
Trifluperazine (Stelazine) OX + + (288)
Trimeprazine (Temaril) LN + + (288)
Triparanol (MER-29) T + + (100)
Ihnicamycin F + (289)
a Legend: +, present; 0, absent.
b Additional brand names are found in The Merck Index.
See Table 2.
d Schistosomes contain myelinoid bodies.
e Retinotoxic.
f Lysosomes of malarial parasites altered, no myelinoid bodies.
g In perfused rat liver.
to the misinterpretation that they are lacking a limiting
membrane (39-42).
Drug-induced myelinoid bodies should be clearly
differentiated from other cellular structures containing
concentrically arranged lamellae (26). Structures simu-
lating DIM bodies can be grouped into categories of
cytoplasmic organelles, secretory granules (43,44),
pigmented granules of neurons (45), storage granules
(46), autophagic vacuoles in cells rich in phospholipids
(47), phagocytic vacuoles oversupplied with phospho-
lipids (42), and secondary lysosomes with a slow
phospholipid breakdown (48,49). The term myelinoid
bodies should not be applied to secondary lysosomes or
vacuoles containing a few membrane fragments or an
occasional myelin figure.
DIM bodies show a superficial resemblance to smooth
fingerprints (50,51) and to whorls formed by smooth
portions of rough cisternae (52), both of which may be
also induced by amphiphilic drugs. Myelinoid bodies
should be distinguished from myelin figures lying free in
the cytoplasm or on the surface of organelles (26,53).
Myelin figures represent bilayered lamellae of amphi-
philic lipids which may arise from altered cellular
membranes, in neutral lipids duringlipolysis (54,55) or
from altered myelin (56). Most often they are artifacts
seen in tissue fixed in aldehydes followed by osmium
tetroxide (57). Extracellular and intraluminal myelin
figures may represent extruded contents of myelinoid
bodies (Fig. 8) (42,58,59).
Biochemical Studies
Since the establishment of the lipid nature of the
material stored within the foam cells and within
myelinoid bodies, various investigators have analyzed
the biochemical composition of organs (60-62), tumor
cells (63), isolated alveolar macrophages and isolated
DIM bodies derived from animals and people treated
with amphiphilic drugs (AP drugs). As reviewed by
Lullmann-Rauch (41), the tissues show a marked in-
crease of total phospholipids (PLs) and variable in-
creases of cholesterol, triglycerides and gangliosides.
The absolute increase in PLs is usually due to an
increase of phosphatidylcholine and in decreasing per-DRUG-INDUCED PULMONARY HISTIOCYTOSIS
FIGURE 8. Renal collecting tubule from a rat treated with chloroquine for 6 weeks. The cells contain numerous myelinoid bodies. The lumen
contains cellular debris with numerous myelinoid bodies and a few mitochondria derived from ruptured proximal cells. x4,000.
centages to phosphatidylinositol, phosphatidylethano-
lamine, bis(monoacylglycero)phosphate (BMGP), sphin-
gomyelin and phosphatidylserine.
Chloroquine and DEAEH increase the incorporation
of glycerol into lysosomal phospholipids, but decrease
its incorporation into microsomal phospholipids. These
drugs greatly increase the synthesis of phosphatidyl-
glycerol in rat liver (64). Homochlorcyclizine induces
accumulation of glycolipids, phosphatidylcholine and
BMGP in the liver (65). The chlorphentermine-induced
accumulation ofglycoproteins and mucopolysaccharides
in culture of intestinal cells is interpreted to be the
consequence of crinophagy rather than endocytosis
(66).
Excessive storage of gangliosides is demonstrable in
miniature pigs treated with chloroquine. In the brain,
GM2 ganglioside increases while phospholipids and
cholesterol are unchanged (67). Skeletal muscle GM2
ganglioside increases 100-fold, BMGP 50-fold and
phospholipids 3-fold (68). Liver, spleen and lungs show a
marked increase of glucosylceramide, GM2 ganglioside
and BMGP (69). Chlorphentermine induces a 14%
increase of GM1 ganglioside in rat brain (70). The
incorporation ofphosphorus into phosphatidylcholine is
reduced and into phosphatidic acid increased by several
amphiphilic drugs studied in cerebral cortex mince (71).
Perhexiline induces the accumulation ofgangliosides in
human liver (72) and perpheral nerve (73) as well as
that of GM3 ganglioside in cultured fibroblasts (74).
Thecomposition ofDIMbodies and oftissues contain-
ingthesebodiesdepends onthetypeoftissueexamined,
the animal species, diet (75), duration oftreatment and
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thetypeofthedrug. Theexcessofhepaticphospholipids
can be explained by the increase of PLs in myelinoid
bodies alone (76). Several investigators studied the
composition of cellular fractions rich in DIM bodies
(33,77,78). The composition ofsmoothmicrosomalmem-
branes from livers of rats treated with AC 3579 for 4
days is altered. The phospholipid/protein ratio is mark-
edly increased while the cholesterol/phospholipid ratio
is decreased. The isolated DIM bodies have a similar
composition, suggesting that the content of myelinoid
bodies could be derived from sequestered membranes of
smooth endoplasmic reticulum. The labeled drug is
found to be selectively concentrated in DIM bodies (79).
The effect of this drug on membrane microviscosity is
cholesterol-like (80). The low cholesterol/phospholipid
ratio in DIM bodies could be the result ofreplacement
of free cholesterol in membranes by the amphiphilic
drugs (76).
Biochemical studies performed on whole lungs or on
isolated alveolar macrophages obtained from animals
treated with AP drugs reveal alterations in the content
and composition oflipids. Cloforex increases the choles-
terol content of rat lung by 50% and the phospholipid
content five times (5). Perhexiline, however, decreases
the concentration of cholesterol, PLs and gangliosides
in rat lungs (61). Alterations induced in the lungs by
chlorphentermine were reported by several investi-
gators. Seiler and Wasserman (81) demonstrated a
marked increase of phosphatidylcholine, and an in-
crease insphingomyelin, free cholesteroland cholesterol
ester. Other investigators observed an increase in total
PLs, phosphatidylcholine, phosphatidylinositol, phos-
phatidylglycerol, sphingomyelin, free cholesterol and
triglycerides (11,82-84). Thefattyacidsofphospholipids
were more saturated, the content of phosphatidyleth-
anolamine was decreased (82) and the surface tension
forces were reduced (85). RMI 10.393 produces changes
similar to those seen with chlorphentermine (86). An
increase ofPLsinthelunglavagefluid occurs early(87).
The alveolar macrophages of rats treated with
chlorphentermine and RMI 10.393 show an increase in
total PLs, phosphatidylcholine, phosphatidylinositol,
phosphatidylglycerol, phosphatidic acid, sphingomyelin
and free cholesterol (11,83,84,88,89). 1-Chloramitryp-
tiline, on the other hand, leads to a slight accumulation
oflecithin and ofphosphatidic acid inthe lung, whilethe
foam cells accumulate cholesterol, cholesterol esters
and free fatty acids. The authors conclude that chlor-
phentermine and RMI 10.393 impair secretory capacity
ofpneumocytes, while chloramitryptiline does not. The
alveolar macrophages induced by chlorphentermine
show an increased lipid peroxidation, probably occur-
ring within lysosomes, as well as augmented antioxi-
dant defense mechanisms (54,90).
A marked increase of the levels of total PLs, total
sterols, BMGP and desmosterol is demonstrable in the
lamellar body fraction isolated from lungs of rats
treated with DEAEH (33). Desmosterol is also found in
fractions containing myelinoid bodies induced by inhibi-
tors of cholesterol synthesis (91,92).
Tissues of animals and patients treated with various
amphiphilic drugs contain an unusual phospholipid,
bis(monoacylglycero)phosphate, or BMGP (33,93-97).
It forms a much greater proportion ofphospholipids in
human tissues than in tissues ofanimals (41,96), proba-
bly because of a difference in drug metabolism (98).
The presence of lysosomal enzymes within DIM
bodies in cells ofdifferent organs and species, after the
administration of various AP drugs, has been repeat-
edlydemonstrated(25,32,41,99-102). Quantitativestud-
ies usually reveal increased activities of acid phos-
phatase, ,-glucuronidase, 3-galactosidase, and de-
creased activities of acid esterase, ,-N-acetylgluco-
saminidase and cathepsin D (62,72,88,103-108). The
levels ofseveral lysosomal enzymes (particularly that of
,B-N-acetylglucosaminidase) offoam cells areincreased,
while acid esterase and a-manosidase are decreased
(23,88,109,110). Chlorcyclizine inhibits the supernatant
enzyme steryl ester hydrolase in vitro (111). Myelinoid
bodiesofchloroquine and DEAEH-treatedrats accumu-
late cholesterol ester because these drugs block its
lysosomal degradation (76).
The accumulation ofPLs within tissues, DIM bodies
and foam cells has been correlated with the accumula-
tion of amphiphilic drugs and of their metabolites.
Several AP drugs and/or their metabolites are localized
mostly in the lung and spleen, and moderately in the
liver, kidney, heart, muscle, adrenals and fat (112-116).
The number ofDIM bodies appears to be related to the
concentration of the drug in a tissue. Correlation
between the concentration of acidic PLs and accumula-
tion of the drug and its metabolites suggesting forma-
tion ofa stable complex is reported by Matsuzawa et al.
(98,117) in livers ofpatients treated with DEAEH. The
bindingofchlorphenterminetophospholipid-rich subcel-
lular fractions is inhibited by desmethylimipramine and
otherbasic amines (118) (Table 1). Several investigators
demonstrated the accumulation of AP drugs within
isolated myelinoid bodies (76,78,119). In addition to
their accumulation within DIM bodies, some AP drugs
form reversible complexes with phospholipids of the
smooth endoplasmic reticulum (120). Such binding may
decrease the activity of microsomal enzymes.
Preferential Organ Involvement
The number ofDIM bodies in a tissue will depend on
the speed with which a given AP drug is metabolized,
the duration of treatment and the dosage of the drug
(121). Potent AP drugs can induce DIM bodies in all
tissues, but the quantity ofDIM bodies will depend on
the cell type. Weak AP drugs induce DIM bodies in a
few cell types only, which usually include the lympho-
cytes. The sensitivity oflymphocytes may be related to
the rapid turnover of glycerolipids in these cells (122).
Perhexiline exemplifies a drug which induces DIM
bodies in an unusual distribution pattern: Myelinoid
bodies are commonly found in the retina, dorsal root
ganglia, adrenal gland and muscle cells ofthe rat, while
they are few in the hepatocytes and lymphocytes, and
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foam cells in the lung are scarce (123). The same drug
is, however, associated with the cirrhosis ofthe liver in
man (124,125).
The difference in the amounts of DIM bodies in
specific organs after treatment with individual AP
drugs is probably related to the lipid composition ofthe
tissue, binding of the drug by the tissue, metabolism
and excretion of the drug. Certain cell types may
contain specific phospholipids for which certain AP
drugs have selective affinities. Thus the absence or
presence ofa specific phospholipid may decide whether
an AP drug will induce myelinoid bodies in one or
another cell type in a given tissue, such as a neuron or
pigment epithelium of the retina (126). The binding of
AP drugs to liposomes made ofdifferent lipids occurs in
this increasing order: sphingomyelin and phosphatidyl-
choline, phosphatidylethanolamine, and phosphatidyl-
serine (127). The divalent chloroquine has a very high
affinity for phosphatidylserine and gangliosides which
may explain its tendency to affect ganglionic cells. The
positively charged adriamycin shows a high affinity for
cardiolipin, which maybe related toits selective toxicity
for mitochondria (128) and its failure to induce typical
myelinoid bodies.
The involvement of the central nervous system de-
pends on the efficiency of the blood-brain barrier
(87,129). The accumulation of AP bodies in liver cells
maybe facilitated bya slowmetabolic inactivation ofthe
drug, fast metabolism of the drug into an active
metabolite and/or by passage of the drug through the
hepatocytes during excretion of the drug in bile.
Several AP drugs are excreted as bile salt-lecithin-drug
micelles (130). The lungs also contain drug-metabolizing
enzymes (131,132).
Uptake ofAmphiphilic Drugs by the Lungs
The uptake of AP drugs has been studied in isolated
perfused lungs of rabbits and rats. The accumulation
has a saturable component and a linear nonsaturable
component. The saturable component is attributed to
specific binding sites orto acarrier-mediated transport.
The linear component is attributed to diffusion to
intracellular and extracellular fluid and to nonspecific
binding to cellular components. The uptake ofthe drug
is directly related to the degree of protonation of the
nitrogen atom and the accumulation is reversible (133).
Minchin et al. (134) suggested that the transport
saturability could be explained either as a carrier-
mediated transport or as an alteration of diffusion
because of drug-induced changes in the fluid state of
membranes. Uptake of chlorphentermine is a Na+
-dependent, carrier-mediated transport process (133).
Methadone forms a slowly effluxable pool in the lung
comparable to chlorphentermine and may be expected
to induce phospholipidosis (135). The uptake of chloro-
quine by pancreatic islets requires neither energy-
dependent active transport norpinocytosis (136). Lungs
of chlorphentermine-pretreated rats accumulate chlor-
phentermine more rapidly than control lungs (137).
Pathogenesis
The storing ofphospholipids and ofamphiphilic drugs
in both myelinoid bodies and vacuoles of alveolar foam
cells suggests that the pathogenesis of both lesions is
similar. The two main factors which should be consid-
ered in the pathogenesis of phospholipid accumulation
within myelinoid bodies are: an increased supply ofPLs
to secondary lysosome through membrane or product
flow (33) and a decreased removal or catabolism of the
contents ofsecondary lysosomes. Decreased catabolism
of lysosomal contents could be associated with forma-
tionofcholesterolprecursors (1,7,8,28,77,78), inhibition
ofthe fusion between primary and secondary lysosomes
(58), direct inactivation of certain lysosomal enzymes
(10,28,33,121) and formation of drug-lipid complexes
with altered physicochemical properties (7,9,10,28,81).
The factors to be considered in the pathogenesis of
the accumulation of phospholipids within intra-alveolar
foam cells are similar to those just listed. The pulmo-
nary PLs are found in the pulmonary surfactant.
Accumulation of foam cells could result from an in-
creased production ofthe surfactant, decreased catabo-
lism ofthe surfactant within pulmonarymacrophages or
decreased removal of the macrophages from the lungs
(8,20,26). The pulmonary surfactant has been shown to
be synthesized in Type II pneumocytes (138,139). It is
catabolized in alveolar macrophages (140) and in Type I
and II pneumocytes (141). The phospholipids of the
surfactant contain about 76% of lecithin (particularly
dipalmitoylphosphatidylcholine), and 11% of phospha-
tidylglycerol. Lamellar inclusion bodies of Type II
pneumocytes have a similar composition. Studies on the
incorporation of labeled palmitic acid into pulmonary
PLs showed that phospholipid storage after chlorphen-
termine and RMI 10.393 is the result of decreased
degradation, while the slight storage ofPLs induced by
chloramitriptyline is the result of marked increase of
synthesis in spite of an increased degradation of PLs
(142).
Fetal lungs ofanimals treated with AP drugs contain
alveolar macrophages (143) or show hyperplasia ofType
II pneumocytes (144). The neonatal lung is, however,
less susceptible to chlorphentermine-induced alveolar
foam cell formation than is the lung of adult rats
(11,23,145,146).
Drug-Lipid Interactions
The majority ofdrugs which induce pulmonary intra-
alveolar histiocytosis and generalized formation of
myelinoid bodies (generalized lipidosis) are cationic
amphiphilic compounds. They contain a hydrophobic
region and a primary or substituted amine group which
canbear anetpositivecharge. Suchcompoundsinteract
with anionic groups of acidic phospholipids (such as
phosphatidate, phosphatidylinositol, phosphatidylser-
ine) of membranes. The hydrophobic regions of the
drugs partition into the membrane. The interaction
leads to neutralization ofthe charges on the phosphate
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groups and to the expulsion of the tightly bound
divalent cations such as calcium. All this leads to
changes in the movement, fusion, permeability, trans-
port and receptor functions of membranes (147-150).
The interaction between various AP drugs and phos-
pholipids was demonstrated by means of nuclear mag-
netic resonance (151,152).
Several authors (41,121) have pointed out that the AP
drugs exist in aprotonized and in a nonprotonized form.
The nonprotonized forms permeate through the plasma
membrane and through lysosomal membranes. The
protonized forms are bound to plasma membrane,
membranes of endoplasmic reticulum and other cyto-
membranes. Nonprotonized molecules enter the lyso-
somes, where they are protonized because of the
strongly acid milieu, increase intralysosomal pH, form
complexes with polar lipids of lysosomal contents and
are thus trapped within the lysosomes (41,121,153).
The administration ofseveral cationic AP drugs leads
to quantitative alterations of phospholipids in various
tissues (84,96,97,122,154-156). In general, the tissues
and lysosomes will contain increased proportions of
anionic phospholipids (phosphatidate, phosphatidylino-
sitol, phosphatidylglycerol, lysobisphosphate) and de-
creased proportions of triglycerides, and of cationic
phospholipids phosphatidylcholine and phosphatidyl-
ethanolamine (157). The quantitative changes in PLs
and the hypotriglyceridemic effects can be explained as
the result of the observed inhibition of the enzymes
phosphatidate phosphohydrolase (91,122,147,158) and
phospholipase, and stimulation of phosphatidate cyti-
dylyltransferase (159) resulting in diversion of phos-
pholipid synthesis from one to another pathway (147,
149).
The accumulation ofphospholipids (PLs) within lyso-
somes can be explained as the result of impaired
degradation of PLs by the lysosomal phospholipase
(121,122,149). The presence of the enzyme phospho-
lipase A has been demonstrated in the plasma mem-
brane, and in microsomal and lysosomal fractions (160).
The lysosomal phospholipase cleaves both fatty acid
ester linkages of lecithin and of phosphatidylethano-
lamine without formation oflyso-forms (161). Various in
vitro and in vivo studies show that the enzyme
phospholipase A (which acts on the hydrophobic group
of the PL) but not phospholipase C (which acts on the
hydrophilic part of the PL molecule) is inhibited by
several amphiphilic drugs (91,119,120,162-164). Follow-
ing the formation of a complex between AP drugs and
PLs, the hydrophilic group of the drug prevents the
formation of the enzyme-substrate complex, while the
hydrophobic group allows penetration of the drug into
the lipid layer and determines the stability of the
drug-lipid complex. Thus, e.g., the hydrophobic group
of AC 3579 is larger than that of AP 22, the AC
3579-lipid complex is more stable and the enzyme
inactivation is more complete than are those of AP 22
(91). Both lysosomal phospholipases have been found
inhibited by chloroquine, DEAEH and aminoglycoside
antibiotics (165,166). Depression oflysosomal phospho-
lipase activities may be also due to the drug-induced
increase of intralysomal pH (153).
The above alterations in enzymes do not explain the
lysosomal accumulation of the anionic phospholipid
bis(monoacylglycero)phosphate (BMGP) also called ly-
sobisphosphatidic acid. BMGP contains very high
amounts of polyenoic fatty acids, particularly docasa-
hexaenoic acid (167,168). It is synthesized in lysosomes
(169,170) by the BMGP synthetase by transfer of acyl
groups from phosphatidylinositol to phosphatidylglyc-
erol orlysophosphatidylglycerol (76). BMGPisresistant
to degradation by lysosomal hydrolases (76). It is a
normal component of lysosomal PLs, where it may
account for 6 to 28% oftotal PLs (76,167,171). Some of
the lysosomal BMGP could have its origin in the plasma
membrane (167).
The lipid composition of myelinoid bodies and conse-
quentlyalso that oftissuesisthus determined inpart by
the type of lipid reaching the lysosomes either by
heterophagy or by autophagy. The formation of myeli-
noid bodies induced by lysergide has been attributed to
increased endocytosis (172) which supplies lipids of
plasma membrane to lysosomes. Autophagy of normal
(173) or hyperplastic smooth endoplasmic reticulum will
supply the lysosomes with excessive lipids characteris-
tic of this organelle. Proliferation of smooth endoplas-
mic reticulum (3,26,62,120,174) associated with en-
hanced drug metabolism of some AP drugs (112,174)
has been observed. Other drugs, such as tilorone and
DEAEH, are, however, knowntodecrease drugmetabo-
lism and phospholipid content of the microsomal frac-
tion (103,175).
Structural Types of Myelinoid Bodies
Myelinoid bodies are secondary lysosomes arising
from the processes of autophagy and heterophagy.
Sequestered and phagocytosed proteins and carbohy-
drates are degraded, while certain lipids resist diges-
tion, because they formed complexes with drugs either
within the lysosomes or prior to their internalization
into the lysosome. The drug-lipid complexes inside the
lysosome are rearranged into lamellar, reticular or
crystalloid structurestoformconcentriclamellar, reticu-
lar and crystalloid myelinoid bodies (26) (Figs. 6 and 7).
Fusion of unicentric lamellar myelinoid bodies gives
origin to multicentric myelinoid bodies. Myelinoid bod-
ies containing parallel lamellae, also called "zebra
bodies," are rarely induced by drugs but are common in
lysosomal storage diseases (176). Concentric lamellae,
reticular patterns and amorphous dense material may
be present in the complex myelinoid body. The crystal-
loid myelinoid bodies contain phospholipids in regular
densely spaced patterns, which are different (square,
rectangular, linear, etc.) according to the plane of
section (Fig. 7). Theyrepresent PLs in hexagonal phase
(177). Their formation is favored by a high lysosomal
content of phosphatidylethanolamine and of highly
unsaturated fatty acids (126,177,178). Studies using in
vitro models showed that the structural patterns of a
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phospholipid depend on the chemical nature ofthe PL,
the presence of fusogenic lipids, the temperature and
hydration (179,180). Increased hydration is associated
with a loose packing of lamellae.
Myelinoid bodies induced by chloroquine contain
abundant clear matrix in addition to lamellae. The
formation ofsuch vacuolated myelinoid bodies has been
attributed to osmotic swelling due to a rapid intra-
lysosomal accumulation of drugs which are not easily
protonized and therefore not absorbed to endoplasmic
reticulum (41).
Myelinoid Bodies Unrelated to Cationic
Amphiphilic Drugs
The epithelial cells of renal proximal tubules are
known to accumulate heterogeneous dense bodies rich
in myelin figures in response to a variety of stimuli
which lead to an increased intake ofPLs. Thus, e.g., an
excessive internalization ofplasmamembraneisinduced
by resorption ofproteins from the glomerular filtrate of
old rats (181). Membranes of hemolyzed erythrocytes
are incorporated by heterophagy (42). The strongly
cationic aminoglycosides gentamycin and netilmicin bind
to the brush border and are reabsorbed by endocytosis,
accumulate in lysosomes, induce myelinoid bodies and
accumulation of phospholipids (182-184). Paraquat is
cationic inits dissolved form andmaybe similarlybound
to acidic phospholipids to form renal DIM bodies (185).
Lysosomes resembling myelinoid bodies are found in the
cells ofthe renal papilla and inner medulla ofpotassium
depleted rats and man (186) as a consequence of an
inadequate intralysosomal metabolism of PLs.
Pathology
The accumulation of pulmonary foam cells and of
myelinoid bodies may be associated with serious alter-
ations ofcellular functions and lead to clinical diseases.
The pathological effect of AP drugs will depend on the
type of cellular membranes to which the drugs are
attached. Thusthe formation ofdrug-lipid complexes in
the plasma membrane may be expected to alter the
membrane flow (187), inhibit membrane internalization
(188)andphagocytosis(189). Chlorpromazine, triparanol
and gentamycin inhibit (Na+ + K+) ATPase activity
(190-192). AP drugs alter permeability of membranes
(193,194). The properties ofmembranes are changed by
an increase in the fluidity ofthe lipid (190,195-197). AP
drugs cause transition oflipid acyl chain from organized
gel to randomized liquid crystalline phase. The phase
transition is associated with a lateral expansion, de-
crease in thickness and density of a membrane, and
with altered function of membrane-bound proteins.
Attachment of the drug to endoplasmic reticulum
may result in the most important functional changes
(28). The alteration of activities of enzymes associated
with membranes were discussed earlier. Presence ofthe
un-ionized drug in the membrane may be responsible
for stabilization of lysosomes and of erythrocytes
(157,198). Additional damage to membranes will de-
pend on the metabolism of AP drugs into either stable
epoxides or less stable arene oxides (199). Membranes
containing drug-lipid complexes are recognized by the
cell as abnormal, and are sequestered by the process of
autophagy leading to the formation of DIM bodies.
Small numbers ofmyelinoid bodies are well tolerated
by the cell. Large numbers may interfere with func-
tional associations between organelles and impair meta-
bolic processes. Cellular death may result for several
reasons. The cell may be compressed in a limited space.
The available pools of phospholipids needed for cell
function and survival may be exhausted (200,201).
Finally the cell may rupture into the lumen of a hollow
structure, as seen in renal tubules (Fig. 8). Presence of
myelin figures in the absence of cellular organelles,
however, does not indicate cell rupture, but it repre-
sents the contents of myelinoid bodies extruded from
the cell (202).
Functional impairment of overloaded macrophages
may lead to a decreased resistance to infections (25). On
the other hand, administration of amphiphilic drugs
may be beneficial in controlling infections. Isolated
alveolar macrophages from animals treated with AP
drugs show an enhanced phagocytic activity and are
more effective in killing bacteria (23). Chloroquine
inhibits infections by enveloped viruses by preventing
theiruncoating within lysosomes (203). Chlorpromazine
and trifluoperazine kill even phagocytized protozoa
(204).
Amphiphilic drugs are known to induce adverse side
effects in man. The foam cell syndrome was known to
occur in Japanese patients since 1965. Yamamoto et al.
(156) established that the syndrome is related to the
intake of diethylaminoethoxyhexestrol and reproduced
it in rats by the same drug. The term "drug-induced
phospholipidosis" was introduced by Shikata et al. (205)
and was popularized by Lullmann-Rauch (41). It indi-
cates a generalized lysosomal storage ofphospholipids.
The drug-induced lysosomal storage differs from inborn
lysosomal storage diseases (27,67,76,101). It has not
been established whetheradministration ofAP drugs to
patients with lysosomal storage diseases will have
adverse effects because of an additional increase in
lysosomal volume. A patient with a subclinical enzyme
deficiency may be expected to develop a clinically
significant disease.
Other clinical adverse effects induced by AP drugs in
man are summarized in Table 4. Some of the serious
adverse effects were discovered only after the drugs
were used by man. The anorectic drugs have been
associated with pulmonary hypertension in patients
with familial predisposition (206). These vascular ef-
fects are related to an altered metabolism of serotonin
rather than to foam cell accumulation (207). Chlorphen-
termine was shown to decrease pulmonary clearance of
5-hydroxytryptamine (208). Most probably other AP
drugs will have clinical side effects. It is therefore
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imperative to search for the ability of each newly
developed drug to induce myelinoid bodies in specific
locations when given in large doses.
In animal experiments, massive accumulation of
pulmonary foam cells is an excellent indicator of a
drug-induced lysosomal storage. It should be remem-
bered, however, that foam cells occur in other pathologi-
cal entities (1) and in old normal rats (209). Preclinical
screening of drugs in intact animals may not identify a
drug as a myelinoid body inducer, if the drug is rapidly
metabolized to aninactive form. This drug may, however,
have adverse effects in a few patients who are unable to
metabolize it. Such a drug may be recognized in in vitro
systems. In performing in vitro studies, we should be
aware of the fact that gentamycin used in cell cultures
has been shown to be an inducer of DIM bodies (210).
The work ofUnsicker et al. (211) with lizards suggests,
that screening methods utilizing cold-blooded animals
are feasible.
Unique pharmacological properties of some AP drugs
will necessitate their clinical use in spite of induction of
DIM bodies. The adverse effects of such drugs will be
more predictable and the clinical use will be safer
provided that the principles ofmyelinoid body formation
and degradation will be established in animal exper-
iments. At first we need studies at cellular level on the
interactions between AP drugs as well as studies on
interactions ofAP drugs with other drugs, food compo-
nents and environmental contaminants. Only a few
structural studies were reported on AP drug interac-
tions (212-214). The type of dietary lipids in the food
may affect the resorption, distribution, retention and
metabolism ofAP drugs. Thus, for example, cholesterol
has been shown to antagonize the phospholipid-drug
interaction in vitro (152).
Equally needed are studies on factors affecting the
disappearance ofmyelinoid bodies afterthe discontinua-
tion of treatment. DIM bodies in animal experiments
and in vitro systems usually disappear in 1 to 10 weeks
(33,62,178,212,215). The recovery in monkeys (216) and
in man (33,72) may take years to be complete. While it is
known that simultaneous administration ofphenobarbi-
tal and chlorphentermine reduces the formation of
alveolarfoamcellsand DIMbodies (132,146) experimen-
tal studies on factors enhancing the resolution of
already accumulated DIM bodies and inclusions in
alveolar foam cells are lacking.
Pulmonary histiocytosis induced by AP drugs de-
serves special consideration of additional factors, such
as the amount of the surfactant available for phago-
cytosis, the metabolism ofdrugs by Clara cells (217) and
the localization of drugs in the lung. The accumulation
of foam cells could be enhanced by simultaneous
administration of drugs and hormones (L-thyroxin)
which increase the amounts of the surfactant within
alveoli either by stimulating the secretion (218) or the
proliferation of type II pneumocytes (219). In this
regard it is of interest that AP drugs are more toxic in
hyperthyroid mice (220).
Drug interactions could also result from the mutual
inhibition of amine accumulation in the lung, and
reversible storage ofdrugs in the lung could precipitate
toxic effects (133). Pathological investigations are
needed to establish whether the adverse effects of AP
drugs on the lungs are potentiated by simultaneous
treatment with drugs known to localize and/or accumu-
late in the lung, such as amphetamine, chloramphet-
amine, desipramine, diphenhydramine, fluphenazine,
methadone, propranolol and tripelenamine (221), and
with drugs which inhibit the binding of chlorphen-
Table 4. Clinical adverse reactions associated with the administration of known inducers of myelinoid bodies.'
Reactionsa
0
c.e >
u~~~~~~o .
Drug ffi ;4 Q) Z : = X ; = E z :t Relierences
4J. 0~~~~~~~~~~~0 0.~~~~~~~~~C 4J0 1. o 0*
Cd CZ U)
Drug Q Z 9) z 0. Z References
Amiodarone + + + (41,121,252,296,305,306)
Chloroquine + + + (41,121)
Chlorpromazine + + (121,297)
Diethylamino-
ethoxyhexestrol + + + + + (33,95,156,205,242)
Gentamycin + (184,298)
Perhexiline + + + (124,125,275,307)
Quinacrine + (259)
Tamoxifen + + (299,303,308)
Tilorone + + (261,262)
Triparanol + + (280,287,300,301)
a + denotes reported.
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termine to the lung, such as pronethalol, pyrilamine,
d-propoxyphene and quinidine (134).
The chemicals which should be studied for their
ability to modify the adverse effects ofAP drugs and for
their potential to induce myelinoid bodies under special
circumstances include: the basic dyes, such as acridine
orange or methylene blue; the lipophilic basic amines
(221); and drugs with amphiphilic molecules, which
were not fully studied. Priority should be given to drugs
currently on the market such as the expectorant
bromhexine; the antihistaminics carbinoxamine, cypro-
heptadine, diphenhydramine, diphenylpyraline, metha-
pyriline, pyrilamine and tripelenamine; the anticholiner-
gics chlorphenoxamine and clofenetamine; the antide-
pressants butriptyline, desipramine, doxepine, protrip-
tyline, trimipramine and zimelidine; the tranquilizers
fluphenazine, promazine andtriflupromazine; theanalge-
sics methadone and d-propoxyphene; the gonad stimu-
lating agents clomiphene and zuclomiphene; the sup-
pressant of lupus erythematosus hydroxychloroquine;
the anorectics phenpentermine and norfenfluramine;
and the adrenergic blockers pronethacol and propran-
olol.
In clinical trials the peripheral blood is easily accessi-
ble for light microscopic and ultrastructural studies.
Lymphocytes and plasma cells of animals and man
respond to AP drugs by formation of vacuoles which
correspond to myelinoid bodies (2,31,32,222). Some AP
drugs such as perhexiline are, however, poor inducers of
myelinoid bodies in lymphocytes (123).
The intra-alveolar accumulation of foamy macro-
phages is a form of pulmonary histiocytosis (7,20).
Experimentally, alveolar foam cells can be induced by
inhalation of aerosols of nickel oxide (223). Large
PAS-positive cells can be induced by Freund's adjuvant
(224) and are seen in tuberculous pneumonia of man
(Fig. 9). These cells have a granular cytoplasm. Cells
seen in lipid pneumonia, on the other hand, contain
vacuoles of different sizes (Fig. 10). Massive accumula-
tion of intra-alveolar histiocytes and hyperplasia of
granular pneumocytes are found also in human and
experimentaldesquamativeinterstitialpneumonia(225-
230). These macrophages are, however, smaller, lack
foamy appearance, and contain PAS-positive granules.
The drug-induced pulmonary histiocytosis (20) and
dlesquamative pneumonia in man (231) may progress to
alveolar proteinosis. The alveoli in alveolar proteinosis
are filled with amorphous, proteinaceous, PAS-positive
material which is rich in lipids and contains phospho-
lipids (232-234). For this reason, the term alveolar
lipoproteinosis is more exact (232). The intra-alveolar
material seen in proteinoses ofdifferent origin is mostly
derived from disintegrated macrophages (235-237) and
from pneumocytes (232,233,238). Although the alveolar
proteinosis induced by AP drugs in animals did not
result in fibrosing alveolitis (21), cholesterol granulo-
mata were observed in lungs of dogs treated with
AY-9944 (1). Alveolar proteinosis is also observed in
FIGURE 9. Alveolar macrophages from a patient with tuberculous
pneumonia. x590.
FIGURE 10. Alveolar macrophage from a patient
monia. x590.
with lipid pneu-
acute silicosis (238,239) and as a response to a variety of
nonspecific chemical irritants (235).
Diagnosis and Treatment
The alveolar proteinosis in man can be diagnosed in
the electron microscope by examination of the sputum
and oflungwashings (240). Controlled volume bronchial
lavage gives a good clinical response in treatment of
alveolar proteinosis (240). Such treatment could be
applied to clinically diagnosed cases of drug-induced
alveolar histiocytosis. The degree of hepatic involve-
ment in generalized lysosomal storage and the recovery
can be followed by the levels of serum transaminases
(72,124,212,241,242). The treatment of symptomatic
generalized drug-induced lysosomal storageisdiscontin-
uation of the drug.
Terminology
Blohm (157) stressed the need for a standard nomen-
clature to facilitate indexing of drug-induced lipidoses.
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We propose the followingterms: drug-induced myelinoid
body, DIM body: (a) concentric lamellar, (b) parallel
lamellar, (c) reticular, (d) crystalloid, (e) mixed type;
drug-induced foam cell; drug-induced lysosomal storage
(lipidosis): (a)generalized, (b) organ-specitic, e.g., renal,
retinal, cerebrospinal (formerly cerebrospinal lipody-
strophy, neuronal storage dystrophy), pulmonary (intra-
alveolar histiocytosis).
Summary
Administration of amphiphilic drugs to experimental
animals causes formation of myelinoid bodies in many
celltypes, accumulation offoamymacrophagesinpulmo-
nary alveoli, and pulmonary alveolar proteinosis. These
changes are the result of an interaction between the
drugs and phospholipids which leads to an alteration in
physicochemicalproperties ofthephospholipids. Impair-
ment ofthe digestion ofaltered pulmonary secretions in
phagosomes of macrophages results in accumulation
of foam cells in pulmonary alveoli. Impairment of
the metabolism of altered phospholipids removed by
autophagy induces an accumulation ofmyelinoid bodies.
The administration of amphiphilic compounds thus
causes pulmonary intra-alveolar histiocytosis which is a
part ofa drug-induced lysosomal storage or generalized
lipidosis.
NOTE ADDED IN PROOF: Amphiphilic drugs have been
the subject of numerous recent studies not otherwise
cited in this review (309-340).
Figure 2 is reproduced with permission ofthe Academic Press. The
secretarial assistance ofMrs. BettyJane Belisle and Mrs. Barbara Ro
is gratefully acknowledged.
REFERENCES
1. Greselin, E. An inhibitor of cholesterol biosynthesis and the
alveolar macrophages. Can J. Comp. Med. Vet. Sci. 30: 121-126
(1966).
2. Lullmann-Rauch, R., and Reil, G. H. Fenfluramine-induced
ultrastructural alterations in tissues of rats and guinea pigs.
Naunyn Schmiedebergs Arch. Pharmacol. 285: 175-184 (1974).
3. Lullmann-Rauch, R., and Scheid, D. Intraalveolar foam cells
associated with lipidosis-like alterations in lung and liver ofrats
treated with tricyclic psychotropic drugs. Virchows Arch. (Cell
Pathol.) 19: 255-268 (1975).
4. Parwaresch, M. R., Reil, G. H., and Seiler, K. U. Studies on
animal and organ specificity of chlorphentermine induced mor-
phological alterations. Res. Exp. Med. (Berlin) 161: 272-288
(1973).
5. Magnusson, G., and Magnusson, 0. Cloforex-induced pulmonary
changes in rats. Beitr. Pathol. 146: 79-88 (1972).
6. Hruban, Z., and Slesers, A. Alterations in outer renal medulla
produced by chloroquine. Fed. Proc. 30: 637 (1971).
7. Hruban, Z., Slesers, A., and Aschenbrenner, I. Pulmonary
intraalveolar histiocytosis induced by drugs. Toxicol. Appl.
Pharmacol. 26: 72-85 (1973).
8. Kikkawa, Y, and Suzuki, K. Alterations ofcellular and acellular
alveolar and bronchiolar walls produced by hypocholesteremic
drug AY 9944. Lab. Invest. 26: 441-447 (1972).
9. Lullmann, H., Lullmann-Rauch, R., and Reil, G. H. A compara-
tive ultrastructural study ofthe effects ofchlorphentermine and
triparanol in rat lung and adrenal gland. Virchows Arch. (Cell
Pathol.) 12: 91-103 (1973).
10. Lullman-Rauch, R., Reil, G. H., Rossen, E., and Seiler, K. U.
The ultrastructure of rat lung changes induced by an anorectic
drug (chlorphentermine). Virchows Arch. (Cell Pathol.) 11:
167-181 (1972).
11. Karabelnik, D., Zbinden, G., and Baumgartner, E. Drug-
induced foam cell reactions in rats. I. Histopathologic and
cytochemical observations after treatment with chlorphenter-
mine, RMI 10.393 and RO 4-4318. Toxicol. Appl. Pharmacol. 27:
395-407 (1974).
12. Staiger, G. R. Light-microscopic demonstration ofdrug-induced
myelin bodies in the liver of rats. Experientia 30: 385-386
(1974).
13. Grabner, R., and Meerbach, W Morphological and biochemical
alterations of the lung after application of chlorphentermine.
Exptl. Pathol. 17:303-311 (1979).
14. Vijeyaratnam, G. S., and Corrin, B. Fine structural alterations
in the lungs of iprindole-treated rats. J. Pathol. 114: 233-239
(1974).
15. Reasor, M. J., Massey, C. A., Koshut, R. A., and Castranova, V
Multinucleation in alveolar macrophages from rats treated with
chlorphentermine. Lab. Invest. 46: 224-230 (1982).
16. Vijeyaratnam, G. S., and Corrin, B. Origin of the pulmonary
alveolar macrophage studied in the iprindole treated rat. J.
Pathol. 108: 115-113 (1972).
17. Flodh, H., and Magnusson, G. Genesis of foam cells: study in
rats after administration of cloforex. Virchows Arch. (Cell
Pathol.) 12: 360-366 (1973).
18. Corrin, B., and King, E. Experimental endogenous lipid pneu-
monia and silicosis. J. Pathol. 97: 325-330 (1969).
19. Smith, R, Heath, D., and Hasleton, P S. Electron microscopy of
chlorphentermine lung. Thorax 28: 559-566 (1973).
20. Vijeyaratnam, G. S., and Corrin, B. Pulmonary alveolar
proteinosis developing from desquamative interstitial pneumo-
nia in long term toxicity studies in the rat. Virchows Arch.
(Pathol. Anat.) 358: 1-10 (1973).
21. Smith, P, Heath, D., and Hasleton, P Effects of prolonged
administration of chlorphentermine on the rat lung. Pathol.
Europ. 9: 273-287 (1974).
22. Bockhardt, H., and Lullmann-Rauch, R. Zimelidine-induced
lipidosis in rats. Acta Pharmacol. Toxicol. 47: 45-48 (1980).
23. Reasor, M. J. Drug-induced lipidosis and the alveolar macro-
phage. Toxicology 20: 1-33 (1981).
24. Wold, J. S., Joost, R. R., Griffing, W J., Marroquine, P, and
Harris, P N. Phospholipid accumulation in rats produced by
fluoxetine and chlorphentermine. Toxicol. Appl. Pharmacol. 37:
118-119 (1976).
25. Hruban, Z., Swift, H., and Slesers, A. Effect of triparanol and
diethanolamine on the fine structure ofhepatocytes and pancre-
atic acinar cells. Lab. Invest. 14: 1652-1672 (1965).
26. Hruban, Z., Slesers, A., and Hopkins, E. Drug-induced and
naturally occurring myeloid bodies. Lab. Invest. 27: 62-70
(1972).
27. Lullmann, H., Lullmann-Rauch, R., and Wassermann, 0. Drug-
induced phospholipidoses. CRC Crit. Rev. Toxicol. 4: 185-218
(1975).
28. De La Iglesia, F A., Feuer, G., McGuire, E. J., and Takada, A.
Morphological and biochemical changes in the liver of various
species in experimental phospholipidosis after diethylamino-
ethoxyhexestrol treatment. Toxicol. Appl. Pharmacol. 34: 28-44
(1975).
29. Ghadially, F N. Ultrastructural Pathology of the Cell. Butter-
worths, London and Boston, 1975.
30. Gray, J. E., Weaver, R. N., Stern, K. F, and Phillips, W A.
Foam cell response in the lung and lymphatic tissues during
long-term high-level treatment with erythromycin. Toxicol.
Appl. Pharmacol. 45: 701-711 (1978).
31. Imoto, S., Hiraide, S., Mitsutani, S., Matsumoto, H., Kaneko,
S., Miyake, T., Akasaka, K., Shinji, Y, Yamamoto, A., Adachi,
S., Fukui, I., Sasaki, H., Mori, Y, and Okada, S. A case ofDRUG-INDUCED PULMONARY HISTIOCYTOSIS 69
drug-induced lipidosis with "sea-blue histiocytes" in the bone
marrow. Japan. Arch. Int. Med. 18: 83-108 (1971).
32. Kitani, T., Yamamoto, A., Adachi, S., Thko, H., Imanaka, T.,
Nasut, T., and Nishikawa, M. Drug-induced lipidosis (IV).
Morphological aspect of leucocytes and bone marrow cells in
human cases and animal experiments induced by 4,4'-diethyl-
aminoethoxyhexestrol. ActaHaematol.Japan35:131-145(1972).
33. Akeda, S. A study on the lipidosis induced by a coronary
vasodilator, 4,4'-diethylaminoethoxyhexestrol dihydrochloride.
Mie Medical J. 22: 65-96 (1972).
34. Gautier, M., Raulin, J., LaPous, D., Loriette, C., Carreau, J. P,
and Scoto, J. Children sea-blue histocytosis (2 cases) compared
wtih phospholipidosis induced by 4-4'DET (4,4'p(diethylamino-
2-ethoxyphenyl)3,4-hexane) inrat. Biomedicine 26: 52-60(1977).
35. Hruban, Z., Spargo, B., Swift, H., Wissler, R. W, and Kleinfeld,
R. Focal cytoplasmic degradation. Am. J. Pathol. 42: 657-683
(1963).
36. Goren, M. B., Hart, P D., Young, M. R., and Amstrong, J. A.
Prevention of phagosome-lysosome fusion in cultured macro-
phages by sulfatides ofmycobacterium tuberculosis. (Proc. Natl.
Acad. Sci. (U.S.) 73: 2510-2514 (1976).
37. Hart, P D'A. Phagosome-lysosome fusion in macrophages: a
hinge in the intracellular fate of ingested microorganisms. In:
Lysosomes in Biology and Pathology (J. T. Dingle, P J. Jacques
and I. H. Shaw, Eds.), Vol. 6, North-Holland, New York, 1979,
pp. 409-423.
38. Mason, R. J., and Williams, M. C. Phospholipid composition and
ultrastructure of A 549 cells and other cultured pulmonary
epithelial cells ofpresumed type II cell origin. Biochim. Biophys.
Acta 617: 36-50 (1980).
39. Drenckhahn, D. Anterior polar cataract and lysosomal alter-
ations in the lens of rats treated with the amphiphilic lipidosis-
inducing drugs chloroquine and chlorphentermine. Virchows
Arch. (Cell Pathol.) 27: 255-266 (1978).
40. Jung, H. J., and Suzuki, K. Morphological changes in CNS of
ratstreated withperhexiline maleate (Pexid). ActaNeuropathol.
(Berlin) 42: 159-164 (1978).
41. Lullmann-Rauch, R. Drug-induced lysosomal storage disorders.
In: Lysosomes in Biology and Pathology (J. T. Dingle, P J.
Jacques and I. H. Shaw, Eds.), Vol. 6, North-Holland, New
York, 1979, pp. 49-130.
42. Torhorst, J., Richter, L., and Rohr, H. P. Entwicklung und
Umwandlung lysosomaler Funktionsformen unter besonderer
Berucksichtigung des glatten endoplasmatischen Reticulum.
Virchows Arch. 343: 64-74 (1967).
43. Quennedy, A., and Brossut, R. Les glandes mandibulaires de
Blaberus craniifer burm. (Dictyoptera, Blaberidae) develop-
ment, structure et fonctionnement. Tissue Cell 7: 503-517
(1975).
44. Riley, J., James, J. L., and Banaja, A. A. The possible role ofthe
frontal and sub-parietal gland systems of the pentastomid
Reighardia sternae (Diesing, 1864) in the evasion of the host
immune response. Parasitology 78: 53-66 (1979).
45. Henkart, M. Lightinducedchangesinthe structureofpigmented
granules in Aplysia neurons. Science 188: 155-157 (1975).
46. Sohal, R. S., Peters, P D., and Hall, T. A. Origin, structure,
composition and age-dependence of mineralized dense bodies
(concretions) in the mid-gut epithelium of the adult housefly
Musca domestica. Tissue Cell 9: 87-102 (1977).
47. Kuhnel, W The glandulae rectales of the rabbit. Z. Zellforsch.
122: 574-583 (1971).
48. Brunck, V, Ericsson, J. L. E., Ponton, J., and Westermark, B.
Residual bodies and "aging" in cultured human glia cells. Exptl.
Cell Res. 79: 1-14 (1973).
49. Vaughan, D. W Membranous bodies in the cerebral cortex of
agingrats: Anelectronmicroscopestudy. J. Neuropathol. Exptl.
Neurol. 35: 152-166 (1976).
50. Del Cerro, M. P, and Snyder, R. S. Studies on dilantin
intoxication. Ultrastructuralanalogieswiththelipidosis. Neurol-
ogy 17: 452-466 (1967).
51. Shinozuka, H., Reid, I. M., Shull, K. H., Liang, H., and Farber,
E. Dynamics of liver cell injury and repair. I. Lab. Invest. 23:
253-267 (1970).
52. Suzuki, K., and De Paul, L. D. Cellular degeneration in
developing central nervous-system ofrats produced by hypocho-
lesterolemic drug AY 9944. Lab. Invest. 25: 546-555 (1971).
53. Le Beux, Y, Hetenyi, G., and Philips, M. J. Mitochondrial
myelin-like figures: a non-specific reactive process of mitochon-
drial phospholipid membranes to several stimuli. Z. Zellforsch.
99: 491-506 (1969).
54. Blanchette-Mackie, E. J., and Scow, R. 0. Retention oflipolytic
products in chylomicroms incubated with lipoprotein lipase:
electron microscope study. J. Lipid Res. 17: 57-67 (1976).
55. Blanchette-Mackie, E. J., and Ucci, A. A. Lamellar structure
and lypolytic activity in hepatic intracellular lipid inclusions. J.
Cell Biol. 70: 285a (1976).
56. Sun, C. N., White, H. J., and Lucas, G. Crystalloid inclusions in
the Schwann cell cytoplasm. Beitr. Pathol. 148: 402-406 (1973).
57. Stock, C., and Grenier, J. F Intracellular and extracellular
myelin bodies in exocrine pancreas of obese hyperglycaemic
mouse. Cytobiologie 12: 111-118 (1975).
58. Abraham, R., and Hendy, R. Effects of chronic chloroquine
treatment on lysosomes ofrat liver cells. Exptl. Mol. Pathol. 12:
148-159 (1970).
59. Zwahlen, R., Richardson, B. R?, and Hauser, R. E. The
production and elimination ofmyeloid bodies by cultured pancre-
atic islet cells. J. Ultrastruct. Res. 67: 340-356 (1979).
60. Hildebrand, J., Thys, O., and Gerin, Y Alterations of rat liver
lysosomes and smooth endoplasmic reticulum induced by the
diazafluoranthen derivative AC-3579. II. Effects ofthe drug on
phospholipid metabolism. Lab. Invest. 28: 83-86 (1979).
61. Hoenig, V, and Werner, F Effect ofperhexiline maleate on lipid
metabolism in the rat. Arzneim. Forsch. 29: 1395-1398 (1979).
62. Thys, O., Hildebrand, J., Gerin, Y, and Jacques, P J. Alter-
ations of rat liver lysosomes and smooth endoplasmic reticulum
induced by the diazafluoranthen derivative AC-3579. I. Morpho-
logic and biochemical lesions. Lab. Invest. 28: 70-82 (1973).
63. Plantavid, M., Chap, H., Lloveras, J., and Douset-Blazy, L.
Cationic amphiphilic drugs as a potential tool for modifying
phospholipids oftumorcells. An in vitro study ofchlorpromazine
effects on Krebs II ascites cells. Biochem. Pharmacol. 30:
293-297 (1981).
64. Matsuzawa, Y., and Hostetler, K. Y. Effects ofchloroquine and
4,4'-bis(diethylaminoethoxy)-a,4-diethyldiphenylethane on the
incorporation of [3H]glycerol into the phospholipids of rat liver
lysosomes and other subcellular fractions, in vivo. Biochim.
Biophys. Acta 620: 592-602 (1980).
65. Lageron, A., and Maziere, J. C. Histoenzymological and
biochemical effects ofhomochlorcyclizine on liver. J. Clin. Chem.
Clin. Biochem. 19: 745 (1981).
66. Blok, J., Mulder-Stapel, A. A., Ginsel, L. A., and Daems, W T.
The effect of chloroquine on lysosomal function and cell-coat
glycoprotein transport in the absorptive cells ofcultured human
small-intestine tissue. Cell Tissue Res. 218: 227-251 (1981).
67. Klinghardt, G. W, Fredman, P, and Svennerholm, L. Chlor-
oquine intoxication induces ganglioside storage in nervous
tissue: A chemical and histopathological study of brain, spinal
cord, dorsal root ganglia, and retina in the miniature pig. J.
Neurochem. 37: 897-908 (1981).
68. Nilsson, O., Fredman, R, Klinghardt, G. W, Dreyfus, H., and
Svennerholm, L. Chloroquine-induced accumulation of ganglio-
sides and phospholipids in skeletal muscles. Eur. J. Biochem.
116: 565-571 (1981).
69. Fredman, R, Klinghardt, G. W, Nilsson, O., and Svennerholm,
L. Lipid accumulation in liver, spleen, lungs and kidneys of
miniature-pigs after chloroquine treatment. Biochem. J. 201:
581-588 (1982).
70. Adachi, M., Tsai, C. Y., Greenbaum, M., Mask, B., and Volk, B.
W Ultrastructure and biochemical studies of rat CNS and
viscera after subcutaneous injection of chlorphentermine. In:
Current Trends in Sphingolipidoses and Allied Disorders (B. W
Volk and L. Schnek, Eds.), Plenum Press, New York, 1976, pp.
429-451.
71. Pappu, A. S., and Hauser, G. Alterations of phospholipid70 Z. HRUBAN
metabolism in rat cerebral cortex mince induced by cationic
amphiphilic drugs. J. Neurochem. 37: 1006-1014 (1981).
72. Lageron, A., Poupon, R., De Saint-Maur, P P, and Levy, V G.
Liver ganglioside storage after perhexyline maleate. Lancet i:
483 (1977).
73. Hauw, J. J., Mussini, J. M., Boutry, J. M., Escourolle, R.,
Pollet, S., Albouz, S., Harpin, M. L., and Baumann, N.
Perhexiline maleate induced lipidoses in human peripheral nerve
and tissue culture: ultrastructural and biochemical changes.
Clin. Toxicol. 18: 1405-1409 (1981).
74. Hauw, J. J., Boutry, J. M., Albouz, S., Harpin, M. L.,
Baudrimont, M., Escourolle, R., and Baumann, N. Perhexiline
maleate-induced lipidoses in cultured human fibroblasts: cell
kinetics, ultrastructuralandbiochemical studies. VirchowsArch.
(Cell Pathol.) 34: 239-249 (1980).
75. Hill, P, and Greselin, F. Lung phospholipids: biochemical and
histologic changes induced bythe cholesterol biosynthesis inhibi-
tor AY-9944. Toxicol. Appl. Pharmacol. 11: 245-256 (1967).
76. Matsuzawa, Y, and Hostetler, K. Y. Studies on drug-induced
lipidosis: subcellular localization ofphospholipid and cholesterol
in the liver of rats treated with chloroquine or 4,4'-bis(diethyl-
aminoethoxy)-ax,1-diethyldiphenylethane. J. Lipid Res. 21:
202-214 (1980).
77. Dietert, S. E., and Scallen, T. J. An ultrastructural and
biochemical study ofthe effects ofthree inhibitors ofcholesterol
biosynthesis upon murine adrenal gland and testis. J. Cell Biol.
40: 44-60 (1969).
78. Yates, R. D., Arai, K., and Rappoport, D. A. Fine structure and
chemical composition ofopaque cytoplasmic bodies oftriparanol-
treated Syrian hamsters. Exptl. Cell Res. 47: 459-478 (1967).
79. May, C., Doriaux, M., Thys, O., Hildebrand, J., and Drochmans,
P Effects ofthe diazafluoranthen derivative AC-3579onrat liver.
A. Isolation and characterization of lamellate cytosomes and
subcellular localization of the drug. Biol. Cellulaire 34: 187-196
(1979).
80. Chatelain, R, and May, C. Abnormal microviscosity oflamellate
cytosomes induced by a diazafluoranthen derivative. Biochem.
Pharmacol. 28: 3467- 3470 (1979).
81. Seiler, K. U., and Wassermann, 0. Drug induced phospho-
lipidosis. II. Alterations in the phospholipid pattern of organs
from mice, rats and guinea pigs after chronic treatment with
chlorphentermine. Naunyn Schmiedebergs Arch. Pharmacol.
288: 261-268 (1975).
82. Gloster, J., Heath, D., Haselton, R, and Harris, P Effect of
chlorphentermine on the lipids ofrat lungs. Thorax 31: 558-564
(1976).
83. Karabelnik, D., Horler, D. A., and Zbinden, G. Lipid distribu-
tion pattern in lungs and alveolar macrophages of rats treated
with 3 foam cell-inducing drugs. Proc. Europ. Soc. Toxicol. 17:
315-321 (1975).
84. Karbelnik, D., and Zbinden, G. Drug-induced foam cell reac-
tions in rats. II. Chemical analysis oflipids stored in lungs and
foam cells aftertreatment with chlorphentermine, 5-[p-(fluoren-
9-ylidenemethyl)phenyl]-2-piperidineethanol (RMI 10.393) and
1-chloramitriptyline. Hoppe Seylers Z. Physiol. Chem. 356:
1151-1160 (1975).
85. Brody, A. R., Clay, M. F., Collins, M. M., Eden, A. C., and
McDermott, M. Effects of chlorphentermine hydrochloride on
the surface tension properties of the rat lung. J. Physiol.
(London) 245: 105P-106P (1975).
86. Hruban, Z., Rubenstein, A. H., and Slesers, A. Alterations in
pancreatic beta cells induced by cyclizine. Lab. Invest. 26:
270-277 (1972).
87. Frisch, W, and Lullmann-Rauch, R. Effects ofseveral lipidosis-
inducing drugs upon the area postrema and adjacent medullary
nuclei of adult rats. Acta Neuropathol. 52: 179-187 (1980).
88. Reasor, M. J., Koshut, R. A., and Castranova, V Biochemical
characteristics of rat alveolar macrophages with chlorphen-
termine-induced phospholipidosis: variations with increasing cell
size. Exptl. Mol. Pathol. 31: 297-307 (1979).
89. Schmien, R., Seiler, K. U., and Wassermann, 0. Drug-induced
phospholipidosis. I. Lipid composition and chlorphentermine
content ofrat lungtissue and alveolar macrophages afterchronic
treatment. Naunyn Schmiedebergs Arch. Pharmacol. 283:
331-334 (1974).
90. Reasor, M.J. Cumenehydroperoxide-mediated lipidperoxidation
in rat alveolar macrophages following induction of phospho-
lipidosis with chlorphentermine. Toxicology 18: 159-168 (1980).
91. Defrise-Quertain, F., Chatelain, P, and Ruysschaert, J. M.
Phospholipase inactivation induced by an aminopiperazine
derivative: A study at the lipid-water interface. J. Pharm.
Pharmacol. 30: 608-612 (1978).
92. Spangler, W L., Adelman, R. D., Conzelman, G. M., and
Ishizaki, G. Gentamycin nephrotoxicity in the dog: Sequential
light and electron microscopy. Vet. Pathol. 17: 206-217 (1980).
93. Adachi, S., Matsuzawa, Y., Yokomura, T., Ishikawa, K., Uhara,
S., Yamamoto, A., and Nishikawa, M. Studies on drug-induced
lipidosis. (V). Changes in the lipid composition of rat liver and
spleen following the administration of 4,4'-dimethylamino-
ethoxyhexestrol. Lipids 7: 1-7 (1972).
94. Tjiong, H. B., and Debuch, H. Lysosomal bis(monoacylglycero)-
phosphate of rat liver, its induction by chloroquine and its
structure. Hoppe-Seylers Z. Physiol. Chem. 359: 71-79 (1978).
95. Yamamoto, A., Adachi, S., Ishibe, T., Shinji, Y., Kaki-uchi, Y.,
Seki, K., and Kitani, T. Accumulation ofacidic phospholipids in a
case of hyperlipidemia with hepatosplenomegaly Lipids 5:
566-571 (1970).
96. Yamamoto, A., Adachi, S., Kitani, T., Shinji, Y, Seki, K., Nasu,
T., and Nishikawa, M. Drug-induced lipidosis in human cases
and in animal experiments. J. Biochem. 69: 613-615 (1971).
97. Yamamoto, A., Adachi, S., Matsuzawa, Y, Kitani, T., Hiraoka,
A., and Seki, K. Studies on drug-induced lipidosis. VII. Effects
ofbis-p-diethylaminoethylether ofhexestrol, chloroquine, homo-
chlorcyclizine, prenylamine, and diazacholesterol on the lipid
composition of rat liver and kidney. Lipids 11: 616-622 (1976).
98. Matsuzawa, Y, Yamamoto, A., Adachi, S., and Nishikawa, M.
Studies on drug-induced lipidosis. VIII. Correlation betwveen
drug accumulation and acidic phospholipids. J. Biochem. 82:
1369-1377 (1977).
99. Fedorko, M. Effect ofchloroquine on morphology ofcytoplasmic
granules in maturing human leucocytes: an ultrastructural
study. J. Clin. Invest. 46: 1932-1942 (1967).
100. Kalina, M., and Bubis, J. J. Myeloid bodies formation in
triparanol treated cultured cells. Virchows Arch. (Cell Pathol.)
19: 349-357 (1975).
101. Staubli, W, Schweizer, W, and Suter, J. Some properties of
myeloid bodies induced in rat liver by an antidepressant drug
(Maprotiline). Exptl. Mol. Pathol. 28: 177-195 (1978).
102. Staubli, W, Schweizer, W, Suter, J., and Hess, R. Ultrastruc-
tural and biochemical action ofbenzoctamine and maprotiline on
the rat liver. Agents Actions 4: 391-403 (1974).
103. De La Iglesia, I. A., Feuer, G., Takada, A., and Matsuda, Y.
Morphologic studies on secondary phospholipidosis in human
liver. Lab. Invest. 30: 539-549 (1974).
104. Kasama, K., Yoshida, K., Takeda, S., Tsujimura, R., and
Hasegawa, S. Inhibitionofacidesteraseinratliverby4,4'-diethyl-
aminoethoxyhexestrol. Lipids 11: 718-721 (1976).
105. Lullmann, H., and Mosinger, E. U. Increased lysosomal enzyme
activities in tissues of rats suffering from chlorphentermine
induced lipidosis. Biochem. Pharmacol. 28: 1015-1016 (1979).
106. Ramsey, R. B., and Fischer, V W The biochemical and morpho-
logical response ofhydrolytic enzymes in the developing brain to
hypocholesterolemic agents. Acta Neuropathol. (Berlin) 49:
89-94 (1980).
107. Ridout, R. M., Decker, R. S., and Wildenthal, K. Chloroquine-
induced lysosomal abnormalities in cultured foetal mouse hearts.
J. Mol. Cell Cardiol. 10: 175-183 (1978).
108. Watts, S. D. M., Orpin, A., and MacCormick, C. Lysosomes and
tegument pathologyinthe chemotherapy ofschistosomiasis with
1,7-bis(p-aminophenoxy)heptane (153C51). Parasitology 78: 287-
294 (1979).
109. Gaton, E., and Wolman, M. Histochemical study on the patho-
genesisofchlorcyclizine-inducedpulmonarylipidosis. Histochem-
istry 63: 203-207 (1979).DRUG-INDUCED PULMONARY HISTIOCYTOSIS 71
110. Reasor, M. J., Trush, M. A., and Walker, E. R. Changes in
lysosomal properties of alveolar macrophages of rats treated
with chlorphentermine. Toxicol. Appl. Pharmacol. 46: 261-264
(1978).
111. Barnhart, J. W The effect of chlorcyclizine on cholesterol
metabolism in mice. Toxicol. Appl. Pharmacol. 27: 449-455
(1974).
112. Burns, J. J. Drug metabolism and teratogenic studies. In:
Environmental Variables in Oral Disease (S. J. Kreshover and F
J. McClure, Eds.), American Association for Advancement of
Science, Washington, DC, 1966, pp. 259-271.
113. Corte, L. D., Gremigni, D., Megazzini, I., Mobilio, R., and
Sgaragli, G. P. Chlorimipramine-induced phospholipidosis: Bio-
chemical and pharmacokinetic observations. Brit. J. Pharmacol.
67: 449P-450P (1979).
114. Eichelbaum, M., Hengstmann, J. H., and Dengler, H. J. Das
Verteilungsmuster des Chlorphentermins bei Ratte, Kaninchen
und Schwein. Naunyn-Schmiedebergs Arch. Pharmakol. Exptl.
Pathol. 267: 446-456 (1970).
115. Kuntzman, R., Klutch, A., Tsai, I., and Burns, J. J. Physiologi-
cal distribution and metabolic inactivation of chlorcyclizine and
cyclizine. J. Pharmacol. Exptl. Therap. 149: 29-35 (1965).
116. Narrod, S. A., Wilk, A. L., and King, C. T. G. Metabolism of
meelizine in the rat. J. Pharmacol. Exptl. Therap. 147: 380-384
(1965).
117. Matsuzawa, Y., Yokomura, T., Ishikawa, K., Adachi, S., and
Yamamoto, A. Studies on drug-induced lipidosis VI. Identi-
fication and determination of the drug and its metabolite in
lipidosis induced by 4,4'-diethylaminoethoxyhexestrol. J. Bio-
chem. 72: 615-621 (1972).
118. Minchin, R. F, Ilett, K. F, andMadsen, B. W Chlorphentermine
binding in rat lung subcellular fractions and its displacement by
desmethylimipramine. Biochem. Pharmacol. 28: 2273-2278
(1979).
119. Chatelain, P, Berliner, C., Ruysschaert, J. M., and Jaffe, J.
Effect of a diazafluoranthen derivative on phospholipases. A
study at the air-water interface. Biochim. Biophys. Acta 419:
540-546 (1976).
120. Laurent, G., Hildebrand, J., and Thys, 0. Alterations of rat
liver lysosomes and smooth endoplasmic reticulum induced by
the diazafluoranthen derivative AC-3579. III. Mechanism and
site of action. Lab. Invest. 32: 580-584 (1975).
121. Seiler, K. U., Thiel, H. J., and Wassermann, 0. Die Chloro-
quinkeratopathie als Beispiel einer arzneimittelinduzierten
Phospholipidosis. Klin. Monatsbl. Augenheilkd. 170: 64-73
(1977).
122. Allan, D., and Michell, R. H. Enhanced synthesis de novo of
phosphatidylinositol inlymphocytes treated with cationic amphi-
philic drugs. Biochem. J. 148: 471-478 (1975).
123. Lullmann, H., and Lullmann-Rauch, R. Perhexiline induces
generalized lipidosis in rats. Klin. Wochenschr. 56: 309-310
(1978).
124. Beaugrand, M., Poupon, R., Levy, V G., Gillard, P, Lageron,
A., Lecomte, D., Darnis, F, andFerrier,J. P Lesions hepitiques
dues au maleate de perhexiline. Etude clinique, biologique,
histopathologique, ultrastructurale et biochimique de 7 cas.
Gastroenterol. Clin. Biol. 2: 579-588 (1978).
125. Pessayre, D., Bichara, M., Feldmann, G., Degott, C., Potet, F,
and Benhamou, J. P Perhexiline maleate-induced cirrhosis.
Gastroenterology 76: 171-177 (1979).
126. Drenckhahn, D., and Liullmann-Rauch, R. Drug-induced retinal
lipidosis: differential susceptibilities of pigment epithelium and
neuroretina toward several amphiphilic cationic drugs. Exptl.
Mol. Pathol. 28: 360-371 (1978).
127. Lullmann, H., andWehling, M. The bindingofdrugs to different
polar lipids in vitro. Biochem. Pharmacol. 28: 3409-3415 (1979).
128. Goormaghtigh, E., Chatelain, P, Caspers, J., and Ruysschaert,
J. M. Evidence of a specific complex between adriamycin and
negatively-charged phospholipids. Biochim. Biophys. Acta 597:
1-14 (1980).
129. Klinghardt, G. W Neuronal storage dystrophy in chronic
chloroquine intoxication. Neurotoxicology 1: 371-380 (1977).
130. Bickel, M. H., and Minder, R. Metabolism and biliary excretion
of the lipophilic drug molecules, imipramine and desmethyl-
imipramine in the rat. II. Uptake into bile micelles. Biochem.
Pharmacol. 19: 2437-2443 (1970).
131. Hook, G. E. R., and Bend, J. R. Pulmonary metabolism of
xenobiotics. Life Sci. 18: 279-290 (1976).
132. Kacev, S., Narbaitz, R., Ruddick, J. A., and Villeneuve, D. C.
Role ofdrugmetabolism inprotection against chlorphentermine-
induced pulmonary phospholipidosis in adult rats. Exptl. Mol.
Pathol. 35: 98-107 (1981).
133. Anderson, M. W, Orton, T. C., Pickett, R. D., and Eling, T. E.
Accumulation of amines in the isolated perfused rabbit lung. J.
Pharmacol. Exptl. Therap. 189: 456-466 (1974).
134. Minchin, R. F., Madsen, B. W, and Ilett, K. E Effect of
desmethylimipramine on the kinetics ofchlorphentermine accu-
mulation in isolated perfused rat lung. J. Pharmacol. Exptl.
Therap. 211: 514-518 (1979).
135. Wilson, A. G. E., Pickett, R. D., Eling, T. E., and Anderson, M.
W Studies on the persistance ofbasic amines in the rabbit lung.
Drug Metabl. Dispos. 7: 420-424 (1979).
136. Tjalve, H., Olsson, S., and Andersson, A. The uptake of
"C-chloroquine by mouse pancreatic islets in vitro. Acta
Pharmacol. Toxicol. 47: 38-44 (1980).
137. Angevine, L. S., Ohmiya, Y, and Mehendale, H. M. Effect of
chlorphentermine pretreatment on chlorphentermine uptake by
isolated perfused rat lung. Drug Metab. Dispos. 10: 68-73
(1982).
138. Buckingham, S., Heinemann, H. O., Sommers, S. C., and
McNary, W I. Phospholipid synthesis in the large pulmonary
alveolar cell. Am. J. Pathol. 48: 1027-1041 (1966).
139. Hallman, M., and Gluck, L. Phosphatidylglycerol in lung
surfactant. II. Subcellular distribution and mechanism ofbiosyn-
thesis in vitro. Biochim. Biophys. Acta 409: 172-191 (1975).
140. Naimark, A. Cellular dynamics and lipid metabolism in the lung.
Fed. Proc. 32: 1967-1971 (1973).
141. Desai, R., Tetley, T. D., Curtis, C. G., Powell, G. M., and
Richards, R. J. Studies on the fate of pulmonary surfactant in
the lung. Biochem. J. 176: 455-462 (1978).
142. Karabelnik, D., and Zbinden, G. Palmitic acid-1-_4C incorpora-
tion and turnover in lung phospholipids of rats treated with
chlorphentermine, RMI 10.393 and RO 4-4318. Arch. Toxicol.
35: 163-174 (1976).
143. Lullmann-Rauch, R. Chlorphentermine-induced ultrastructural
alterations in foetal tissues. Virchows Arch. (Cell Pathol.) 12:
295-302 (1973).
144. Kikkawa, Y., and Motoyama, E. K. Effect of AY-9944, a
cholesterol biosynthesis inhibitor on fetal lung development and
on the development of type II alveolar epithelial cells. Lab.
Invest. 28: 48-54 (1973).
145. Kacew, S., Narbaitz, R., and Dubas, T. C. Biochemical and
morphologic investigation of the influence of chlorphentermine
and subsequent withdrawal on newborn rat lung. Toxicol. Appl.
Pharmacol. 47: 185-191 (1979).
146. Kacew, S., and Narbaitz, R. The effect of phenobarbital on
chlorphentermine-induced lipidosis-like alterations in renal tis-
sue ofadult and newborn rats. Virchows Arch. (Cell Pathol.) 36:
59-63 (1981).
147. Brindley, D. N., Allan, D., and Michell, R. H. The redirection of
glyceride and phospholipid synthesis by drugs including chlor-
promazine, fenfluramine, imipramine, mepyramine and local
anaesthetics. J. Pharm. Pharmacol. 27: 462-464 (1975).
148. Lullmann, H., Plosch, H., and Ziegler, A. Ca replacement by
cationic amphiphilic drugs from lipid monolayers. Biochem.
Pharmacol. 29: 2969- 2974 (1980).
149. Michell, R. H., Allan, D., Bowley, M., and Brindley, D. N. A
possible metabolic explanation fordrug-induced phospholipidosis.
J. Pharm. Pharmacol. 28: 331-332 (1976).
150. Schwarting, H., Seiler, K. U., and Wassermann, 0. On the
mechanism ofdrug-induced phospholipidosis. Naunyn Schmiede-
bergs Arch. Pharmacol. (Suppl.) 293: R57 (1976).
151. Seydel, J. K., and Wassermann, 0. NMR-studies on the molecu-
lar basis of drug-induced phospholipidosis. Naunyn Schmiede-72 Z. HRUBAN
bergs Arch. Pharmacol. 279: 207-210 (1973).
152. Seydel, J. K., and Wassermann, 0. NMR-studies on the molecu-
lar basis of drug-induced phospholipidosis. II. Interaction be-
tween several amphiphilic drugs and phospholipids. Biochim.
Pharmacol. 25: 2357-2364 (1976).
153. Ohkuma, S., and Poole, B. Fluorescence probe measurement of
the intralysosomal pH in living cells and the perturbation ofpH
by various agents. Proc. Natl. Acad. Sci. (U.S.) 75: 3327-3331
(1978).
154. Kasama, K., Yoshida, K., Takeda, S., Akeda, S., and Kawai, K.
Bis-(monoacylglyceryl)phosphate and acyl phosphatidylglycerol
isolated from human livers of lipidosis induced by 4,4'-diethyl-
aminoethoxyhexestrol. Lipids 9: 235-243 (1974).
155. Wherrett, J. R., and Huterer, S. Bis-(monoacylglyceryl)-ph )s-
phate of rat and human liver: fatty acid composition and NI R
spectroscopy. Lipids 8: 531-533 (1973).
156. Yamamoto, A., Adachi, S., Ishikawa, K., Yokomura, T., Kitani,
T., Nasu, T., Imoto, T., and Nishikawa, M. Studies on drug-
induced lipidosis. III. Lipid composition of the liver and some
other tissues in clinical cases of "Niemann-Pick-like syndrome"
induced by 4,4'-diethylaminoethoxyhexestrol. J. Biochem. 70:
775-784 (1971).
157. Blohm, T. R. Drug-induced lysosomal lipidosis: biochemical
interpretations. Pharmacol. Rev. 30: 593-603 (1979).
158. Brindley, D. N., and Bowley, M. Drugs affecting the synthesis of
glycerides and phospholipids in rat liver. Biochem. J. 148:
461-469 (1975).
159. Bowley, M., Cooling, J., Burditt, S. L., and Brindley, D. N. The
effects ofamphiphilic cationic drugs and inorganic cations on the
activity of phosphatidate phosphohydrolase. Biochem. J. 165:
447-454 (1977).
160. Colbeau, A., Cuault, F, and Vignais, P M. Characterization and
subcellular localization of lipase activities in rat liver cell.
Comparison withphospholipase A. Biochimie 56: 275-288 (1974).
161. Mellors, A., and Tappel, A. L. Hydrolysis ofphospholipids by a
lysosomal enzyme. J. Lipid Res. 8: 479-485 (1967).
162. Grabner, R. Action of chlorphentermine on the hydrolysis of
phosphatidylcholine by phospholipase A2. Exptl. Pathol. 13:
68-77 (1977).
163. Hostetler, K. Y., and Matsuzawa, Y. Studies on the mechanism
ofdrug-induced lipidosis. Cationic amphiphilic druginhibition of
lysosomal phospholipases A and C. Biochem. Pharmacol. 30:
1121- 1126 (1981).
164. Kunze, H., Nahas, N., Traynor, J. R., and Wurl, M. Effects of
local anesthetics on phospholipases. Biochim. Biophys. Acta 441:
93-102 (1976).
165. Hostetler, K. Y., and Hall, L. B. Inhibition ofkidney lysosomal
phospholipases A and C by aminoglycoside antibiotics: possible
mechanism of aminoglycoside toxicity. Proc. Natl. Acad. Sci.
(U.S.) 79: 1663-1667 (1982).
166. Matsuzawa, Y., and Hostetler, K. Y Inhibition of lysosomal
phospholipase A and phospholipase C by chloroquine and 4,4'-
bis(diethylaminoethoxy)-a,3-diethyldiphenylethane. J. Biol.
Chem. 255: 5190- 5194 (1980).
167. Stremmel, W, and Debuch, H. Bis(monoacylglycero)phos-
phate-a marker lipid of secondary lysosomes. Hoppe-Seylers
Z. Physiol. Chem. 357: 803-810 (1976).
168. Tjiong, H. B., Lepthin, J.., and Debuch, H. Lysosomal
phospholipids from rat liver after treatment with different
drugs. Hoppe-Seylers Z. Physiol. Chem. 359: 63-67 (1978).
169. Bleistein, J., Debuch, H., and Gunawan, J. Metabolism of
phosphatidylglycerol byliverlysosomes ofchloroquine-pretreated
rats. Hoppe-Seylers Z. Physiol. Chem. 361: 1445-1448 (1980).
170. Frentzen-Bertrams, M., and Debuch, H. Production ofbis(mono-
acylglycero)phosphate fromphosphatidylglycerol inisolated lyso-
somes ofchloroquine-pretreated rats. Hoppe-Seylers Z. Physiol.
Chem. 362: 1229-1236 (1981).
171. Wherrett, J. R., and Huterer, S. Enrichment of bis-(monacyl-
glyceryl)phosphate in lysosomes from rat liver. J. Biol. Chem.
247: 4114-4120 (1972).
172. Hendelman, W J. A morphologic study ofthe effects of LSD on
neurons in cultures of cerebellum. J. Neuropathol. Exptl.
Neurol. 31: 411-432 (1972).
173. Trout, J. J., Stauber, W T., and Schottelius, B. A. Increased
autophagy in chloroquine-treated tonic and phasic muscles: an
alternative view. Tissue Cell 13: 393-401 (1981).
174. Gerber, N., and Arnold, K. The effect of diphenyl-piperazine
compounds and other agents on diphenhydantoin, zoxazolamine
and hexobarbital metabolism. J. Pharmacol. Exptl. Therap. 164:
232-238 (1968).
175. Leeson, G. A., Biedenbach, S. A., Chan, K. Y, Gibson, J. P,
and Wright, G. J. Decrease in the activity of the drug-
metabolizing enzymes ofrat liver following the administration of
tilorone hydrochloride. Drug Metab. Dispos. 4: 232-238 (1976).
176. Hers, H. G., and Van Hoff, F (Eds.). Lysosomes and Storage
Diseases. Academic Press, New York, 1973.
177. Buchheim, W, Drenckhahn, D., and Lullmann-Rauch, R.
Freeze-fracture studies of cytoplasmic inclusions occurring in
experimental lipidosis as induced by amphiphilic cationic drugs.
Biochim. Biophys. Acta 575: 71-80 (1979).
178. Lullmann-Rauch, R. Retinal lipidosis in albino rats treated with
chlorphentermine and with tricyclic antidepressants. Acta
Neuropathol. (Berlin) 35: 55-67 (1976).
179. Howell, J. I., Fisher, D., Goodall, A. H., Verrinder, M., and
Lucy, J. A. Interactions of membrane phospholipids with
fusogenic lipids. Biochim. Biophys. Acta 332: 1-10 (1973).
180. Junger, E., and Reinauer, H. Liquid crystalline phases of
hydrated phosphatidylethanolamine. Biochim. Biophys. Acta
183: 304-308 (1969).
181. Cain, H., and Kraus, B. Lysosomal pigmentary deposits in the
kidney of old Wistar rats. Virchows Arch. (Cell Pathol.) 10:
322-338 (1972).
182. Feldman, S., Wang, M. Y, and Kaloyanides, G. J. Amino-
glycosides induce a phospholipidosis in the renal cortex of the
rat: An early manifestation of nephrotoxicity. J. Pharmacol.
Exptl. Therap. 220: 514-520 (1982).
183. Kosek, J. C., Mazze, R. I., and Cousins, M. J. Nephrotoxicity of
gentamycin. Lab. Invest. 30: 48-57 (1974).
184. Luft, F C., Yum, M. N., Walker, P D., and Kleit, S. A.
Gentamicin gradient patterns and morphological changes in
human kidneys. Nephron 18: 167-174 (1977).
185. Fowler, B. A., and Brooks, R. E. Effects of the herbicide
paraquat on the ultrastructure of mouse kidney. Am. J. Pathol.
63: 505-512 (1971).
186. France, R., Gray, M. E., Stone, W J., and Swift, L. L.
Intracellular granules ofthe renal medulla in a case ofpotassium
depletion due to renal potassium wasting. Am. J. Pathol. 91:
299-312 (1978).
187. Morre, J., Kartenbeck, J., and Frane, W W Membrane flow and
interconversions among endomembranes. Biochim. Biophys.
Acta 559: 71-152 (1979).
188. Hruban, Z., Tavoloni, N., Reed, J. S., and Boyer, J. L.
Ultrastructural changes during cholestasis induced by chlor-
promazine in the isolated perfused rat liver. Virchows Arch.
(Cell Pathol.) 26: 289-305 (1978).
189. Kvarstein, B., and Stormorken, H. Influence of acetylsalicylic
acid, butazolidine, colchicine, hydrocortisone, chlorpromazine
and imipramine on the phagocytosis of polystyrene latex parti-
cles by human leucocytes. Biochem. Pharmacol. 20: 119- 124
(1971).
190. Keeffe, E. B., Blankenship, N. M., and Scharschmidt, B. F
Alteration of rat liver plasma membrane fluidity and ATPase
activity by chlorpromazine hydrochloride and its metabolites.
Gastroenterology 79: 222-231 (1980).
191. Mizuno, G. R., Chapman, C. J., Chipault, J. R., and Pfeiffer, D.
R. Lipidcomposition and(Na+ + K+)-ATPaseactivityinratlens
duringtriparanol-induced cataract formation. Biochim. Biophys.
Acta 664: 1-12 (1981).
192. Williams, P D., Holohan, P D., and Ross, C. R. Gentamycin
nephrotoxicity I. Acute biochemical correlates in rats. Toxicol.
Appl. Pharmacol. 61: 234-242 (1981).
193. Bermejo, J., Fernandez, P, Tato, F, and Belmonte, A.
Desmethylimipramine induced changes inliposomalmembranes.
Res. Commun. Chem. Pathol. Pharmacol. 8: 101-113 (1974).DRUG-INDUCED PULMONARY HISTIOCYTOSIS 73
194. Tsao, S. C., Iga, T., Sugiyama, Y., and Hanano, M. Effect of
chlorpromazine on isolated rat hepatocytes. Biochem. Pharmacol.
31: 491-497 (1982).
195. Cater, B. R., Chapman, D., Hawes, S. M., and Saville, J. Lipid
phase transitions and drug interactions. Biochim. Biophys. Acta
363: 54-69 (1974).
196. Jain, M. K., Wu, N. Y, and Wray, L. V Drug-induced phase
change in bilayer as possible model of action of membrane
expanding drugs. Nature 255: 494-495 (1975).
197. Rothman, J. E. The molecular basis of mesomorphic phase
transitions in phospholipid systems. J. Theor. Biol. 38: 1-16
(1973).
198. Watts, S. D. M., and Atkins, A. M. Effects of the schisto-
somicide, 1,7-bis(p-aminophenoxy)heptane (153C51) on lyso-
somes and membrane stability. Biochem. Pharmacol. 28: 2579-
2584 (1979).
199. Perel, J. M. Pharmacokinetics oftherapeutic and toxic reactions:
II. Tricyclic antidepressants. Neurotoxicology 1: 157-161 (1977).
200. Anzil, A. R, Herrlinger, H., and Blinzinger, K. Ultrastructural
observation on the cytoplasmic inclusions ofnervous tissues and
peripheral myopathy induced in suckling mice by chlorphen-
termine administration. Neurotoxicology 1: 485-491 (1977).
201. Drenckhahn, D., and Lullmann-Rauch, R. Lens opacities associ-
ated with lipidosis-like ultrastructural alterations in rats treated
with chloroquine, chlorphentermine or iprindole. Exp. Eye Res.
24: 621-632 (1977).
202. Abraham, R., Hendy, R., and Grasso, P Formation of myeloid
bodies in rat liver lysosomes after chloroquine administration.
Exptl. Mol. Pathol. 9: 212-229 (1968).
203. Miller, D. K., and Lenard, J. Antihistaminics, local anesthetics,
and other amines as antiviral agents. Proc. Natl. Acad. Sci.
(U.S.) 78: 3605-3609 (1961).
204. Pearson, R. D., Manian, A. A., Harcus, J. L., Hall, D., and
Hewlett, E. L. Lethal effect of phenothiazine neuroleptics on
the pathogenic protozoan, Leishmania donavani. Science 217:
369-371 (1982).
205. Shikata, T., Kanetaka, T., Endo, Y, and Nagashima, K.
Drug-induced generalized phospholipidosis. Acta Pathol. Japan
22: 517-531 (1972).
206. Dukes, M. N. G. (Ed.) Side Effects ofDrugs Annual 3. Excerpta
Medica, Amsterdam, 1977.
207. Mielke, H., Seiler, K. U., Stumpf, U., and Wassermann, 0. Uber
eine Beziehung zwischen dem Serotoninstoffwechsel und der
pulmonalen Hypertonie bei Ratten nach Gabe verschiedener
Anorektika. Z. Kardiol. 62: 1090-1098 (1973).
208. Angevine, L. S., and Mehendale, H. M. Effect of chlorphen-
termine on the pulmonary disposition of5-hydroxytryptamine in
the isolated perfused rabbit lung. Am. Rev. Resp. Dis. 122:
891-898 (1980).
209. Flodh, H., Magnusson, G., and Magnusson, 0. Pulmonary foam
cells in rats of different age. Z. Versuchstierkd. 16: 299-312
(1974).
210. Aubert-Tulkens, G., Van Hoff, F, and Tulkens, P Gentamicin-
induced lysosomal phospholipidosis in cultured rat fibroblasts.
Lab. Invest. 40: 481-491 (1979).
211. Unsicker, K., Allan, I. J., and Newgreen D. F 'Extraneuronal
effects of 6-hydroxydopamine and extraneuronal uptake of
noradrenaline. In vivo and in vitro studies on adrenocortical
cells of lizards and rats. Cell Tissue Res. 173: 45-69 (1976).
212. Gray, J. E., Purmalis, A., Purmalis, B., and Mathews, J.
Ultrastructural studies ofthe hepatic changes brought about by
clindamycin and erythromycin in animals. Toxicol. Appl. Phar-
macol. 19: 217-233 (1971).
213. Loker, E., Scallen, T. J., and Diettert, S. E. Phenobarbital-
induced proliferation of smooth endoplasmic reticulum after
administration of triparanol. Anat. Rec. 168: 221-225 (1970).
214. Svendsen, 0. Effect of phenobarbital on chlorphentermine
induced alveolar foam cells in rats. Toxicol. Appl. Pharmacol. 40:
171-173 (1977).
215. Kim, S. U. Effects of the cholesterol biosynthesis inhibitor AY
9944 on organotypic cultures of mouse spinal cord. Retarded
myelinogenesis and induction of cytoplasmic inclusions. Lab.
Invest. 32: 720-728 (1975).
216. Rosenthal, A. R., Kolb, H., Bergsma, D., Huxsoll, D., and
Hopkins, J. L. Chloroquine retinopathy in the rhesus monkey.
Invest. Ophthalmol. Vis. Sci. 17: 1158-1175 (1978).
217. Serabjit-Singh, C. J., Wolf, C. R., Philpot, R. M., and Plopper,
C. G. Cytochrome P-450: localization in rabbit lung. Science 207:
1467-1470 (1980).
218. Redding, R. A., Doublas, W H. J., and Stein, M. Thyroid
hormone influence upon lung surfactant metabolism. Science
175: 994-996 (1972).
219. Hook, G. E. R., and DiAugustine, R. P Secretory cells of the
peripheral pulmonary epithelium as targets for toxic agents.
Environ. Health Perspect. 16: 147-156 (1976).
220. Ashford, A., and Ross, J. W Toxicity of depressant and
antidepressant drugs in hyperthyroid mice. Brit. Med. J. 2:
217-218 (1968).
221. Philpot, R. M., Anderson, M. W, and Eling, T. E. Uptake,
accumulation, and metabolism of chemicals by the lung. In:
Metabolic Function of the Lung. (Y. S. Bakhle and J. R. Vane,
Eds.), Marcel Dekker, New York, 1977, pp. 123-171.
222. Lullmann-Rauch, R., and Pietschmann, N. Lipidosis-like cellu-
lar alterations in lymphatic tissues ofchlorphentermine-treated
animals. Virchows Arch. (Cell Pathol.) 15: 295-308 (1974).
223. Bingham, E., Barkley, W, Zerwas, M., Stemmer, K., and Taylor,
P Responses ofalveolar macrophages to metals. I. Inhalation of
lead and nickel. Arch. Environ. Health 25: 406-414 (1972).
224. Deodhar, S. D., and Bhagwat, A. G. Desquamative-interstitial
pneumonia-like syndrome in rabbits. Arch. Pathol. 84: 54-58
(1967).
225. Brewer, D. B., Heath, D., and Asquith, P Electron microscopy
of desquamative interstitial pneumonia. J. Pathol. 97: 317-323
(1969).
226. Corrin, B., and Price, A. B. Electron microscopic studies in
desquamative interstitial pneumonia associated with asbestos.
Thorax 27: 324-331 (1972).
227. Farr, G. H., Harley, R. A., and Hennigar, G. R. Desquamative
interstitial pneumonia. An electron microscopic study. Am. J.
Pathol. 60: 347-370 (1970).
228. Heath, D. Desquamative interstitial pneumonia. Thorax 23: 330
(1968).
229. Rhodes, M. L. Desquamative interstitial pneumonia. New
ultrastructural findings. Am. Rev. Respir. Dis. 108: 950-954
(1973).
230. Shortland, J. R., Drake, C. S., and Crane, W A. J. Electron
microscopy of desquamative interstitial pneumonia. Thorax 24:
192-208 (1969).
231. Bhagwat, A. G., Wentworth, P, and Conen, P E. Observations
on the relationship of desquamative interstitial pneumonia and
pulmonary alveolar proteinosis in childhood: a pathologic and
experimental study. Chest 58: 326-332 (1970).
232. Heppleston, A. G., Wright, N. A., and Stewart, J. A. Experi-
mental alveolar lipo-proteinosis following the inhalation ofsilica.
J. Pathol. 101: 293-307 (1970).
233. Kuhn, C., Gyorkey, G., Levine, B. E., and Ramirez, R. J.
Pulmonary alveolar proteinosis. A study using enzyme, histo-
chemistry, electron microscopy and surface tension measure-
ments. Lab. Invest. 15: 492-509 (1966).
234. Rosen, S. H., Castleman, B., and Liebow, A. A. Pulmonary
alveolar proteinosis. N. Engl. J. Med. 258: 1123-1142 (1958).
235. Davidson, J. M., and Macleod, W M. Pulmonary alveolar
proteinosis. Brit. J. Dis. Chest 63: 13-28 (1969).
236. Divertie, M. B., Brown, A. L., and Harrison, E. G. Pulmonary
alveolar proteinosis. Two cases studied by electron microscopy.
Am. J. Med. 40: 351-359 (1966).
237. Schober, R., Kosek, J. C., and Bensch, K. G. The origin ofthe
membranaceous intralveolar material in pulmonary alveolar
proteinosis. Lab. Invest. 30: 388-389 (1974).
238. Lamberty, J., Hoffmann, E., and Pizzolato, P The ultrastruc-
ture of acute silicosis in humans. Am. J. Pathol. 70: 34a-35a
(1973).
239. Hoffmann, E. O., Lamberty, J., Pizzolato, P, and Coover, J. The
ultrastructure of acute silicosis. Arch. Pathol. 96: 104-10774 Z. HRUBAN
(1973).
240. Costello, J. F, Moriarty, D. C., Branthwaite, M. A., Thrner-
Warwick, M., and Corrin, B. Diagnosis and management of
alveolar proteinosis: the role of electron microscopy. Thorax 30:
121-132 (1975).
241. Gleiser, C. A., Bay, W, Dukes, T. W, Brown, R. S., Read, W K.,
and Pierce, K. R. Study on chloroquine toxicity and a drug-
induced cerebrospinal lipodystrophy in swine. Am. J. Pathol. 53:
27-45 (1968).
242. Itoh, S., and Tsukada, Y. Clinico-pathological and electron
microscopical studies on a coronary dilating agent: 4,4'-diethyl-
aminoethoxyhexestrol-induced liver injuries. Acta Hepatogas-
troenterol. 20: 204- 215 (1973).
243. Bockhardt, H., Drenckhahn, D., and Lullmann-Rauch, R.
Generalisierte Lipidose bei der Ratte nach Behandlung mit
Amiodaron und Zimelidin. Verh. Anat. Ges. 72: 417-418 (1978).
244. Theiss, E., Hummler, H., Lengsfeld, H., Staiger, G. R., and
Tranzer, J. P Lipidspeicherung bei Versuchstieren nach Vera-
breichung trizyklischer Amine. Schweiz. Med. Wochenschr. 103:
424 (1973).
245. Brown, E. A. B. The localization, metabolism and effects of
drugs and toxicants in lung. Drug Metab. Rev. 3: 33-87 (1974).
246. Ryrfeldt, A. The distribution, elimination, and biotransforma-
tion of 14C-Cloforex in the mouse and rat. Acta Pharmacol.
Ibxicol. (Copenh.) 28: 391-405 (1970).
247. Mazue, G., Berthe, J., Newmann, A. J., and Brunaud, M. A
toxicologic evaluation of ethyl fluclozepate (CM 6912). Int. J.
Clin. Pharmacol. Therap. Ibxicol. 19: 453-472 (1981).
248. Kacew, S., and Narbaitz, R. A comparative ultrastructural and
biochemical study between the effects of chlorphentermine and
phentermine onrat lung. Exptl. Mol. Pathol. 27: 106-120 (1977).
249. Franken, G., Luillmann, H., and Siegfriedt, A. The occurrence
ofhuge cells in pulmonary alveoli ofrats treated by an anorexic
drug. Arzneim. Forsch. 20: 417 (1970).
250. Heath, D., Smith, P, andHasleton, P Effectofchlorphentermine
on the rat lung. Thorax 28: 551-558 (1973).
251. Eling, T. E., Pickett, R. D., Orton, T. C., and Anderson, M. W
A study of the dynamics of imipramine accumulation in the
isolated perfused rabbit lung. Drug Metab. Dispos. 3: 389-399
(1975).
252. D'Amico, D. J., Kenyon, K. R., and Ruskin, J. N. Amiodarone
keratopathy. Drug-induced lipid storage disease. Arch. Ophthal-
mol. 99: 257-261 (1981).
253. Yates, R. D., Chen, I. L., and Mascorro, J. A. Somemorphologi-
cal effects of20,25-diazacholesterol (SC-12937) on adrenocortical
cells of the Syrian hamster. Tex. Rep. Biol. Med. 26: 241-248
(1968).
254. Batty, H. K., and Millhouse, 0. E. Ultrastructure of the Gunn
rat substantia nigra I. Cytoplasmic changes. Acta Neuropathol.
35: 93-107 (1976).
255. Schutta, H. S., andJohnson, L. Bilirubin encephalopathy in the
Gunn rat. A fine structural study of the cerebellar cortex. J.
Neuropathol. Exptl. Neurol. 26: 377-396 (1967).
256. Kacew, S., and Narbaitz, R. Early metabolic alterations in
pulmonary tissue following administration oftoxic agents. Fed.
Proc. 37: 2489-2495 (1978).
257. Hassenpflug, J. Further studies on the structure-activity rela-
tionship of drugs inducing lipidosis-like ultrastructural alter-
ations. Naunyn-Schmiedebergs Arch. Pharmakol. 293 (Suppl):
R57 (1976).
258. Grunnet, M. L. Effects of nortriptyline and other psychotropic
drugs on neurons and glia in vitro: an ultrastructural study
Neurotoxicology 1: 163-170 (1977).
259. Grant, W M. Toxicology of the eye. Charles C Thomas,
Springfield, IL, 1974.
260. Merrill, T. G., Payne, B. J., and Tbusimis, A. J. Cytoplasmic
granules in lymphocytes from rats dosed with SK&F 14336-D.
In: Proceedings 29th Annual Meeting, Electron Microscopy
Society ofAmerica (C. J. Arceneaux, Ed.), Claitor's Publishing
Division, Baton Rouge, LA, 1971, pp. 556-557.
261. Weiss, J. N., Weinberg, R. S., and Regelson, W Keratopathy
after oral administration of tilorone hydrochloride. Am. J.
Ophthalmol. 89: 46-53 (1980).
262. Weiss, J. N., Ochs, A. L., Abedi, S., and Selhorst, J. B.
Retinopathy after tilorone hydrochloride. Am. J. Ophthalmol.
90: 846-853 (1980).
263. Drenckhahn, D., and Lullmann-Rauch, R. Drug-induced experi-
mental lipidosis in the nervous system. Neuroscience 4: 697-712
(1979).
264. Thompson, S. W, Antonchak, B., Matthews, J. R., and Katz, R.
Chloroquine induced retinal gangliopathy. Bull. Soc. Pharmacol.
Environ. Pathol. 3: 2-24 (1975).
265. Fedorko, M. E. Effect of chloroquine on morphology of leuko-
cytes and pancreatic exocrine cells from the rat. Lab. Invest. 18:
27-37 (1968).
266. Drenckhahn, D., and Lullmann-Rauch, R. Experimental myopa-
thy induced by amphiphilic cationic compounds including several
psychotropic drugs. Neuroscience 4: 549-562 (1979).
267. Rawlins, F A., and Uzman, B. G. Effect of AY-9944, a
cholesterol biosynthesis inhibitor on peripheral nerve myelina-
tion. Lab. Invest. 23: 184-189 (1970).
268. Abraham, R., and Hendy, R. Irreversible lysosomal damage
induced by chloroquine in the retinae of pigmented and albino
rats. Exptl. Mol. Pathol. 12: 185-200 (1970).
269. Read, W K., and Bay, W W Basic cellular lesions in chloroquine
toxicity. Lab. Invest. 24: 246-259 (1971).
270. Tousimis, A. J., and Barron, C. N. Chlorpromazine and the eye
of the dog. Exptl. Mol. Pathol. 13: 89-110 (1970).
271. Wong, T.-W, and Hruban, Z. Testicular degeneration and
necrosis induced by chlorcyclizine. Lab. Invest. 26: 278-299
(1972).
272. Houghton, D. C., Hartnett, M., Campbell-Boswell, M., Porter,
G., and Bennett, W A light and electron microscopic analysis of
gentamycin nephrotoxicity in rats. Am. J. Pathol. 82: 589-612
(1976).
273. Lhermitte, F, Fardeau, M., Chedru, F., and Mallecourt, J.
Polyneuropathy after perhexiline maleate therapy. Brit. Med. J.
1: 1256 (1976).
274. Mussini, J. M., Hauw, J. J., and Escourolle, R. Etude en
microscopie electronique des l6sions nerveuses, musculaires et
cutanees determin&es par le perhexiline. Acta Neuropathol. 38:
53-59 (1977).
275. Nick, J., Dudognon, P, Escourolle, R., Bakouche, P, Nicolle,
M. H., Regnier, A., Hauw, J. J., Ermidou, S., Pollet, S.,
Baumann, N., Singlas, E., and Levy, J. Manifestations neuro-
logiques en rapport avec le traitement par le maleate de
perhexiline. Rev. Neurol. (Paris) 134: 103-114 (1978).
276. Chen, I. L., and Yates, R. 0. Anultrastructural studyofopaque
cytoplasmic inclusions induced by triparanol treatment. Am. J.
Anat. 121: 705-726 (1976).
277. Diener, R. M., and Hsu, B. Y. D. Effects of certain basic
phenolic ethers on the rat fetus. Toxicol. Appl. Pharmacol. 10:
565-567 (1967).
278. Schutta, H. S., and Neville, H. E. Effects of cholesterol
synthesis inhibitors on the nervous system. Lab. Invest. 19:
487-493 (1968).
279. Yates, R. D. The effects of triparanol on adrenocortical cells of
the zona fasciculata ofSyrian hamsters. Z. Zellforsch. 71: 41-52
(1966).
280. James-Kracke, M. R., Sloane, B. F, Schuman, H., and Somlyo,
A. P Lysosomal composition in cultured vascular smooth muscle
cells: Electron probe analysis. Proc. Natl. Acad. Sci. (U.S.) 76:
6461- 6465 (1979).
281. Dubois-Dalcq, J., Buyse, M., DeBruyne, J., Van Tilghen, H.,
and Thiry, L. Ultrastructural study of the action of amino-
piperazines on transformed cell lines and on nervous system
tissue culture. Exptl. Cell Res. 77: 303-311 (1973).
282. Goodwin, L. G., Richards, W H. G., and Udall, V The toxicity
of diaminodiphenoxyalkanes. Brit. J. Pharmacol. 12: 468-474
(1957).
283. Drenckhahn, D., Kleine, L., and Lullmann-Rauch, R. Lyso-
somal alterations in cultured macrophages exposed to anorexi-
genic and psychotropic drugs. Lab. Invest. 35: 116-123 (1976).
284. Cowger, M. L. Mechanism ofbilirubin toxicity on tissue cultureDRUG-INDUCED PULMONARY HISTIOCYTOSIS 75
cells. Factors that affect toxicity, reversibility by albumin, and
comparison with other respiratory poisons and surfactants.
Biochem. Med. 5: 1-16 (1971).
285. Silberberg, D. H., and Schutta, H. S. The effects ofunconjugated
bilirubin and related pigments on cultures of rat cerebellum. J;
Neuropathol. Exptl. Neurol. 26: 576-583 (1967).
286. Alexander, N. J. Ultrastructural changes in rat epididymis after
vasectomy. Z. Zellforsch. 136: 177-182 (1973).
287. Liveson, J. A., Gardner, J., and Bornstein, M. B. Tissue culture
studies ofpossible uremic neurotoxins: Myoinositol. Kidney Int.
12: 131-136 (1977).
288. West, N. R. Response of rat dorsal root and superior cervical
ganglion cultures to congeners of chlorpromazine. Proc. Fourth
Ann. Meet. Soc. Neuroscience 4: 474 (1974).
289. Glassy, M. C., and Ferrone, S. Ultrastructural alterations in
human lymphoblastoid B cell lines treated with tunicamycin.
Am. J. Pathol. 103: 1-9 (1981).
290. Fedorko, M. E., Hirsch, J. G., and Cohn, Z. A. Autophagic
vacuoles produced in vitro. I. Studies on cultured macrophages
exposed to chloroquine. J. Cell Biol. 38: 377-391 (1968).
291. Tischner, K. Effects of chloroquine on neurons of long-term
cultures of peripheral and central nervous system. Acta
Neuropathol. (Berlin) 28: 233-242 (1974).
292. Warhurst, D. C., and Hockley, D.J. Modeofactionofchloroquine
on Plasmodium berghei and R cynomolgi. Nature 214: 935-936
(1967).
293. Brosnan, C. F., Bunge, M. B., and Murray, M. R. The response
of lysosomes in cultured neurons to chlorpromazine. J. Neuro-
pathol. Exptl. Neurol. 29: 337-353 (1970).
294. Lageron, A., Scotto, J., and Gautier, M. Effects ofpexid on liver
cell cultures. Ultrastructural and histoenzymological studies.
Eur. J. Clin. Pharmacol. 19: 417-421 (1981).
295. Le Gall, J. Y., Guillouzo, A., Glaise, D., Deugnier, Y., Messner,
M., and Bourel, M. Perhexiline maleate toxicity on human liver
cell lines. Gut 21: 977-984 (1980).
296. Dugognon, R, Hauw, J. J., De Baecque, C., Escourolle, R.,
Derrida, J. P, and Nick, J. Neuropathie a l'amiodarone: lipidose
medicamenteuse. Nouv. Presse Med. 8: 1766-1767 (1979).
297. Buffaloe, W J., Johnson, A. W, and Sandifer, M. G. Total dosage
of chlorpromazine and ocular opacities. Am. J. Psychiatry 124:
250-251 (1976).
298. Wellwood, J. M., Simpson, P M., Tighe, J. R., and Thompson,
A. E. Evidence of gentamycin nephrotoxicity in patients with
renal allografts. Brit. Med. J. 3: 278-281 (1975).
299. McKeown, C. A., Swartz, M., Blom. J., and Maggiano, J. M.
Tamoxifen retinopathy. Brit. J. Ophthalmol. 65: 177-179 (1981).
300. Kirby, T. S. Cataracts produced by triparanol (MER/29). Trans.
Am. Ophthalmol. Soc. 65: 493-543 (1967).
301. McPherson, J. R., and Shorter, R. G. Intestinal lesions associ-
ated with triparanol. A clinical and experimental study. Am. J.
Dig. Dis. 10: 1024-1033 (1965).
302. Hruban, Z. Pulmonary changes induced by amphophilic drugs.
Environ. Health Perspect. 16: 111-118 (1976).
303. Lullmann, H., and Lullmann-Rauch, R. Tamoxifen-induced
generalized lipidosis in rats subchronically treated with high
doses. Tbxicol. Appl. Pharmacol. 61: 138-146 (1981).
304. Thelmo, W L., and Levine, S. Renal lesions induced by tilorone
and an analog. Am. J. Pathol. 91: 355-360 (1978).
305. Marchlinski, E E., Gansler, T. S., Waxman, H. L., andJosephson,
M. E. Amiodarone pulmonary toxicity. Ann. Int. Med. 97:
839-845 (1982).
306. Gefter, W B., Epstein, D. M., Pietra, G. G., and Miller, W T.
Lungdisease caused by amiodarone, a new antiarrythmic agent.
Radiology 147: 339-344 (1983).
307. Pieterse, A. S., Rowland, R., and Dunn, D. Perhexiline maleate
induced cirrhosis. Pathology 15: 201-203 (1983).
308. Vinding, T., and Nielsen, N. V Retinopathy caused by treatment
with Tamoxifen in low dosage. Acta Ophthalmol. 61: 45-50
(1983).
309. Albert, C., and Lullmann-Rauch, R. Ultrastructural altera-
tions in peripheral nerve trunks of rats subehronically treated
with chlorphentermine or perhexiline. Drug Res. 33: 125-127
(1983).
310. Angevine, L. S., and Mehendale, H. M. Chlorphentermine
uptake by isolated perfused rabbit lung. Ibxicol. Appl. Pharm-
acol. 52: 336-346 (1980).
311. Drenckhahn, D., Jacobi, B., and Liullmann-Rauch, R. Corneal
lipidosis in rats treated with amphiphilic cationic drugs. Arzneim.
Forsch. 33(1): 827-831 (1983).
312. Ferin, J. Alveolar macrophage mediated pulmonary clearance
suppressed by drug-induced phopholipidosis. Exp. Lung. Res.
4: 1-10 (1982).
313. Fredman, R, Klinghardt, G. W, Nilsson, O., and Svennerholm,
L. Lipid accumulation in liver, spleen, lungs and kidneys of
miniature pigs after chloroquine treatment. Biochem. J. 201:
581-588 (1982).
314. Freise, J., Magerstedt, R, and Schmid, K. Inhibition of phos-
pholipase A2 by gabexate mesilate, camostate and aprotinine.
Enzyme 30: 209-212. (1983).
315. Gairola, C., Matulionis, D. H., and Reasor, M. J. Chlor-
phentermine-induced alterations in the lungs of vitamin E-
deficient and supplemented rats. Biochemical and morphometric
analysis of the pulmonary response. Exptl. Mol. Pathol. 38:
368-379 (1983).
316. Hirst, L. W. Sanborn, G., Green, R., Miller, N. R., and Heath,
W D. Amodiaquine ocular changes. Arch. Ophthalmol. 100:
1300-1304 (1982).
317. Hostetler, K. Y., and Richman, D. D. Studies on the mechanism
ofphospholipid storage induced by amantadine and chloroquine
in Madin Darby canine kidney cells. Biochem. Pharmacol. 31:
3795-3799 (1982).
318. Houghton, D. C., Plamp, C. E., DeFehr, J. M., Bennett, W H.,
Porter, G., and Gilbert, D. Gentamicin and tobramicin nephro-
toxicity. A morphologic and functional comparison in the rat.
Am. J. Pathol. 93: 137-152 (1978).
319. Kacew, S. Alterations in newborn and adult rat lungmorphology
andphospholipid levelsafterchlorcyclizineandchlorphentermine
treatment. Ibxicol. Appl. Pharmacol. 65: 100-108 (1982).
320. Kunze, H., Hesse, B., and Bohn, E. Effects of antimalarial
drugs on several rat-liver lysosomal enzymes involved in phos-
phatidylethanolamine catabolism. Biochim. Biophys. Acta 713:
112-117 (1982).
321. Lageron, A., and Saffroy, M. Morphological histochemical bio-
chemical changes induced by homochlorcyclizine in rat. Acta
Histochem. 71: 103-110 (1982).
322. Lehnert, B. E., and Ferin, J. Particle binding, phagocytosis, and
plastic substrate adherence characteristics of alveolar macro-
phages from rats acutely treated with chlorphentermine. J.
Retic. Soc. 33: 293-303 (1983).
323. Lockard, V G., Watson, S. A., Siraj, M. Y, Hayes, A. W, and
O'Neal, R. M. Rubratoxin B hepatotoxicity: an electron micro-
scopic study. Exptl. Mol. Pathol. 34: 94-109 (1981).
324. Lullmann-Rauch, R., and Nassberger, L. Citalopram-induced
generalized lipidosis in rats. Acta Pharmacol. Toxicol. 52:
161-167 (1983).
325. Lullmann-Rauch, R. Experimentally induced lipidosis in rat
retinal pigment epithelium. Arch. Klin. Ophthalmol. 215: 297-
303 (1981).
326. Lullmann-Rauch, R. Histochemical evidence for lysosomal stor-
age of acid glycosaminoglycans in splenic cells of rats treated
with tilorone. Histochemistry 76: 71-87 (1982).
327. Lullmann-Rauch, R., and Reil, G. H. Chlorphentermine-induced
lipidosis-like ultrastructural alterations in lungs and adrenal
glands ofseveral species. Tbxicol. Appl. Pharmacol. 30: 408-421
(1974).
328. Lullmann-Rauch, R., and Stoermer, B. Generalized lipidosis in
newborn rats and guinea pigs induced during prenatal develop-
mentbyadministrationofamphiphilicdrugstopregnantanimals.
Virchows Arch. (Cell Pathol.) 39: 59-73 (1982).
329. Matulionis, D. H., Gairola, C., and Reasor, M. J. Chlor-
phentermine-induced alterations in the lungs of vitamin E-
deficient and -supplemented rats: quantitative ultrastructural
analysis oftype II cell response. Exptl. Mol. Pathol. 39: 80-88
(1983).76 Z. HRUBAN
330. McNamara, T. E., Goodloe, S., and Butkus, D. E. Myeloid
bodies in patients without clinical Fabry's disease. Arch. Pathol.
Lab. Med. 104: 14-16 (1980).
331. Montgomery, M. R., Furry, J. M., and Reasor, M. J. Chlor-
phentermine inhibits oxidative energy metabolism in rat lung
slices. Tbxicol. Appl. Pharmacol. 65: 63-68 (1982).
332. Ohmiya, Y., Angevine, L. S., and Mehendale, H. M. Effect of
drug-induced phospholipidosis on pulmonary disposition of
pneumophilic drugs. Drug Metab. Dispos. 11: 25-30 (1983).
333. Pappu, A. S., and Hauser, G. Phospholipid metabolism changes
in rat tissues in vitro after injections of propranolol. J.
Pharmacol. Exptl. Therap. 222: 109-115 (1982).
334. Reasor, M. J., and Heyneman, C. A. Disaturated phosphatidyl-
choline in the pulmonary airspaces of rats treated with
chlorphentermine. Biochem. Pharmacol. 32: 939-941 (1983).
335. Reasor, M. J., Heyneman, C. A., and Walker, E. R. Chlor-
cyclizine-induced pulmonary phospholipidosis in rats. Res.
Comm. Chem. Pathol. Pharmacol. 38: 235-246 (1982).
336. Reasor, M. J., Koshut, R. A., McNulty, M. J., and Trush, M. A.
Chemiluminescence from rat alveolar macrophages following
induction of phospholipidosis with chlorphentermine. Toxicol.
Appl. Pharmacol. 52: 497-506 (1980).
337. Rees, S., Constantopoulos, G., Barranger, J. A., and Brady,
R. 0. Organomegaly and histopathology in an animal model of
mucopolysaccharidosis induced by suramin. Naunyn-Schmiede-
berg's Arch. Pharmacol. 319: 262-270 (1982).
338. Tashiro, Y, Watanabe, Y, and Enomoto, Y Experimental
phospholipidosis induced by 4,4'-diethyl-aminoethoxyhexestrol.
Acta Pathol. Japan. 33: 929-942 (1983).
339. Thoma-Laurie, D. L., Walker, E. R., and Reasor, M. Chlor-
phentermine-induced neonatal and maternal pulmonary phos-
pholipidosis in rats. Exptl. Mol. Pathol. 38: 310-321 (1983).
340. Watanabe, M. Drug-induced lysomal changes and nephrotoxicity
in rats. Acta Pathol. Japan. 28: 867-889 (1978).